Chromosome	Position	G_change	P_change	Exon_order	Gene	Transcript	Disease	Drug	Drug_status	Evidence
chr14	105243048	G>T	Q79K	exon_3	AKT1	ENST00000554581	Cutaneous melanoma	[]		Case report
chr14	105246551	C>T	E17K	exon_2	AKT1	ENST00000554581	Cutaneous melanoma	[]		Case report
chr9	133748283	C>T	T315I	exon_6	ABL1	ENST00000318560	Any cancer type	Axitinib		Pre-clinical
chr9	133748282	A>G	T315A	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133748288	T>C	F317L	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133748288	T>G	F317V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133748288	T>A	F317I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133748289	T>G	F317C	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133738357	T>C	Y253H	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133738363	G>A	E255K	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133738364	A>T	E255V	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133748414	T>G	F359V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133748415	T>G	F359C	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
chr9	133748414	T>A	F359I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	NCCN guidelines
					ARAF		Colorectal adenocarcinoma	[]		Case report
chr9	133747588	G>C	V299L	exon_5	ABL1	ENST00000318560	Any cancer type	Cabozantinib		Pre-clinical
chr9	133747588	G>C	V299L	exon_5	ABL1	ENST00000318560	Any cancer type	Crizotinib		Pre-clinical
chr9	133748414	T>G	F359V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	NCCN guidelines
chr9	133748415	T>G	F359C	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	NCCN guidelines
chr9	133748414	T>A	F359I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	NCCN guidelines
chr9	133738357	T>C	Y253H	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	NCCN guidelines
chr9	133738363	G>A	E255K	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	NCCN guidelines
chr9	133738364	A>T	E255V	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	NCCN guidelines
					ARAF		Colorectal adenocarcinoma	[]		Case report
chr9	133747588	G>C	V299L	exon_5	ABL1	ENST00000318560	Any cancer type	ForetinibÂ 		Pre-clinical
					B2M		Cutaneous melanoma	[]		Case report
chr9	133748282	A>G	T315A	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	NCCN guidelines
chr9	133748288	T>C	F317L	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	NCCN guidelines
chr9	133748288	T>G	F317V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	NCCN guidelines
chr9	133748288	T>A	F317I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	NCCN guidelines
chr9	133748289	T>G	F317C	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	NCCN guidelines
chr9	133747588	G>C	V299L	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	NCCN guidelines
chr9	133748283	C>T	T315I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia;Acute lymphoblastic leukemia	Ponatinib	Approved	FDA guidelines
chr9	133748283	C>T	T315I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Ponatinib	Approved	NCCN guidelines
chr9	133747588	G>C	V299L	exon_5	ABL1	ENST00000318560	Any cancer type	Vandetanib		Pre-clinical
chr14	105246551	C>T	E17K	exon_2	AKT1	ENST00000554581	Any cancer type	[]	Clinical Trials	Pre-clinical
chr14	105246551	C>T	E17K	exon_2	AKT1	ENST00000554581	Any cancer type	[]		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Lung adenocarcinoma	[]		Case report
chr7	140481402	C>G	G469A	exon_11	BRAF	ENST00000288602	Lung adenocarcinoma	[]		Case report
chr14	105246551	C>T	E17K	exon_2	AKT1	ENST00000554581	Any cancer type	[]	Clinical Trials	Early trials
chr14	105246551	C>T	E17K	exon_2	AKT1	ENST00000554581	Head an neck squamous	[]		Case report
chr14	105239908	G>A	H238Y	exon_8	AKT1	ENST00000554581	Fibrous histiocytoma	Everolimus		Case report
chr14	105246551	C>T	E17K	exon_2	AKT1	ENST00000554581	Endometrium	Tensirolimus		Early trials
chr2	29443697	A>G	F1174L	exon_23	ALK	ENST00000389048	Lung adenocarcinoma	[]		Pre-clinical
chr2	29416730	T>A	E1408V	exon_29	ALK	ENST00000389048	Lung adenocarcinoma	Brigatinib		Case report
chr2	29443631	G>T	L1196M	exon_23	ALK	ENST00000389048	Lung adenocarcinoma	Brigatinib		Case report
					ALK		Lung adenocarcinoma	Ceritinib		FDA guidelines
					CTNNB1		Colorectal adenocarcinoma	[]		Pre-clinical
chr2	29443631	G>T	L1196M	exon_23	ALK	ENST00000389048	Lung adenocarcinoma	Ceritinib		FDA guidelines
chr2	29443600	G>T	S1206Y	exon_23	ALK	ENST00000389048	Lung adenocarcinoma	Ceritinib		FDA guidelines
chr2	29432682	C>G	G1269A	exon_25	ALK	ENST00000389048	Lung adenocarcinoma	Ceritinib		FDA guidelines
chr2	29445213	A>G	I1171T	exon_22	ALK	ENST00000389048	Lung adenocarcinoma	Ceritinib		FDA guidelines
					EGFR		Glioma	[]		Early trials
					EGFR		Lung	[]		Late trials
chr7	55242511	G>T	D761Y	exon_19	EGFR	ENST00000275493	Non-small cell lung	[]		Case report
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Non-small cell lung	[]		Late trials
					EGFR		Glioma	[]		Early trials
chr2	29455235	A>G	F856S	exon_15	ALK	ENST00000389048	Acute myeloid leukemia	Crizotinib		Pre-clinical
chr2	29754892	G>T	A348D	exon_4	ALK	ENST00000389048	Acute myeloid leukemia	Crizotinib		Pre-clinical
chr2	29443625	G>A	L1198F	exon_23	ALK	ENST00000389048	Lung adenocarcinoma	Crizotinib		Case report
chr2	29432664	C>T	R1275Q	exon_25	ALK	ENST00000389048	Glioma	Crizotinib		Pre-clinical
chr2	29445450	C>G	G1128A	exon_21	ALK	ENST00000389048	Glioma	Crizotinib		Pre-clinical
chr2	29445213	A>T	I1171N	exon_22	ALK	ENST00000389048	Glioma	Crizotinib		Pre-clinical
chr2	29443642	C>G	R1192P	exon_23	ALK	ENST00000389048	Glioma	Crizotinib		Pre-clinical
chr2	29436859	A>C	F1245C	exon_24	ALK	ENST00000389048	Glioma	Crizotinib		Pre-clinical
chr2	29445258	C>T	C1156Y	exon_22	ALK	ENST00000389048	Lung adenocarcinoma	Lorlatinib		Pre-clinical
					APC		Colorectal adenocarcinoma	[]		Pre-clinical
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Non-small cell lung	[]		Late trials
					EGFR		Glioma	[]		Early trials
					FBXW7		Any cancer type	[]		Pre-clinical
chrX	47426121	C>G	S214C	exon_7	ARAF	ENST00000377045	Lung adenocarcinoma	Sorafenib	FDA approved	Case report
					ARID1A		Any cancer type	[]		Pre-clinical
					ARID1A		Ovary	[]		Pre-clinical
					ARID1A		Any cancer type	[]		Pre-clinical
chr4	1807494	G>A	V555M	exon_13	FGFR3	ENST00000440486	Myeloma	[]		Pre-clinical
					ATM		Colorectal adenocarcinoma	[]		Case report
					ATM		Lymphoma	[]		Pre-clinical
					ATM		Stomach	[]		Early trials
					ATM		Bladder	Cisplatin	Approved	Early trials
					ATM		Stomach;Prostate adenocarcinoma	Olaparib		Early trials
					ATM		Glioma	Temozolomide		Pre-clinical
					ATR		Ovary;Any cancer type	Olaparib	Approved	Pre-clinical
					ATR		Glioma	Temozolomide		Pre-clinical
					BAP1		Mesothelioma	[]		Pre-clinical
					BAP1		Cutaneous melanoma	[]		Pre-clinical
					BAP1		Renal;Any cancer type	[]		Pre-clinical
					BCOR		Stomach	Enzastaurin		Pre-clinical
					JAK1		Colorectal adenocarcinoma	[]		Case report
					JAK1		Cutaneous melanoma	[]		Case report
					JAK2		Cutaneous melanoma	[]		Case report
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	[]		Pre-clinical
					BRAF		Colorectal adenocarcinoma	[]		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	[]		Pre-clinical
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Thyroid	[]		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	[]		Pre-clinical
chr7	140453145	A>C	L597R	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	[]		Case report
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Glioma	[]		Pre-clinical
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Ovary	[]		Case report
					KRAS		Pancreas	[]		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	[]		Pre-clinical
chr7	140481402	C>G	G469A	exon_11	BRAF	ENST00000288602	Head an neck squamous	[]		Case report
chr7	140477854	A>C	L485W	exon_12	BRAF	ENST00000288602	Billiary tract	[]		Case report
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Lung adenocarcinoma	[]		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Thyroid	[]		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Ovary	[]		Pre-clinical
					BRAF		Any cancer type	[]		Pre-clinical
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	[]		Early trials
chr7	140453133	T>C	K601R	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	[Trametinib]		Case report
chr7	140453145	A>C	L597R	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	[Trametinib]		Case report
chr7	140453136	AC>CT	V600R	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	[Trametinib]		Case report
chr12	25398281	C>T	G13D	exon_2	KRAS	ENST00000256078	Colorectal adenocarcinoma	Cetuximab		Late trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Lung adenocarcinoma;Thyroid	Dabrafenib		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Non-small cell lung	Dabrafenib		NCCN guidelines
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Dabrafenib	Approved	FDA guidelines
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Gastrointestinal stromal	Dabrafenib		Case report
chr7	140453136	AC>CT	V600R	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Dabrafenib		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Colorectal adenocarcinoma	Dabrafenib;Trametinib		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Neuroendocrine	Dabrafenib;Trametinib		Case report
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Lung adenocarcinoma	Dabrafenib;Trametinib		FDA guidelines
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Dabrafenib;Trametinib	Approved	FDA guidelines
chr7	140453136	AC>TT	V600K	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Dabrafenib;Trametinib	Approved	FDA guidelines
chr7	140481411	C>A	G466V	exon_11	BRAF	ENST00000288602	Lung adenocarcinoma	Dasatinib		Pre-clinical
chr7	140481393	T>C	Y472C	exon_11	BRAF	ENST00000288602	Lung adenocarcinoma	Dasatinib		Case report
					BRAF		Colorectal adenocarcinoma	Irinotecan;Vemurafenib;Cetuximab		Early trials
					KRAS		Lung	Selumetinib		Early trials
					BRAF		Colorectal adenocarcinoma	Panitumumab;Dabrafenib;BYL719	Approved; Approved;Clinical Trials	Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Colorectal adenocarcinoma	Panitumumab;Dabrafenib;Trametinib	Approved; Approved;Clinical Trials	Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Malignant astrocytoma	PLX4720		Pre-clinical
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Pediatric glioma	Selumetinib	Clinical Trials	Early trials
chr7	140453154	T>C	D594G	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Sorafenib		Pre-clinical
chr7	140481402	C>T	G469E	exon_11	BRAF	ENST00000288602	Cutaneous melanoma	Sorafenib		Pre-clinical
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Trametinib	Approved	FDA guidelines
chr7	140453136	AC>TT	V600K	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Trametinib	Approved	FDA guidelines
					NRAS		Colorectal adenocarcinoma	Cetuximab	Approved	NCCN guidelines
chr7	140453135	CA>GT	V600D	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Vemurafenib	Approved	NCCN guidelines
chr7	140453136	AC>TT	V600K	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Vemurafenib	Approved	NCCN guidelines
chr7	140453137	C>T	V600M	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Vemurafenib	Approved	NCCN guidelines
chr7	140453136	A>C	V600G	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Vemurafenib	Approved	NCCN guidelines
chr7	140453136	AC>CT	V600R	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Vemurafenib	Approved	NCCN guidelines
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Lung adenocarcinoma;Hairy-Cell leukemia;Myeloma	Vemurafenib	Approved	Case report
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Malignant astrocytoma	Vemurafenib	Approved	Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Vemurafenib	Approved	FDA guidelines
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Thyroid carcinoma	Vemurafenib	Approved	Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Approved	NCCN guidelines
chr7	140453135	CA>GT	V600D	exon_15	BRAF	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Approved	NCCN guidelines
chr7	140453136	AC>TT	V600K	exon_15	BRAF	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Approved	NCCN guidelines
chr7	140453137	C>T	V600M	exon_15	BRAF	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Approved	NCCN guidelines
chr7	140453136	A>C	V600G	exon_15	BRAF	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Approved	NCCN guidelines
chr7	140453136	AC>CT	V600R	exon_15	BRAF	ENST00000288602	Non-small cell lung;Lagerhans cell histiocytosis;Erdheim-Chester histiocytosis	Vemurafenib	Approved	NCCN guidelines
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Vemurafenib;Cobimetinib	Approved	FDA guidelines
chr7	140453136	AC>TT	V600K	exon_15	BRAF	ENST00000288602	Cutaneous melanoma	Vemurafenib;Cobimetinib	Approved	FDA guidelines
					BRCA1		Ovary	[]		Early trials
					BRCA1		Pancreas	[]		Case report
					BRCA1		Any cancer type	[]		Case report
					BRCA1		Breast adenocarcinoma	[Olaparib]		Early trials
					BRCA1		Prostate adenocarcinoma	Olaparib		Early trials
					BRCA1		Ovary	Olaparib	Approved	FDA guidelines
					BRCA1		Breast adenocarcinoma	Platinum Agent		Early trials
					BRCA1		Ovary	Platinum Agent		Late trials
					BRCA1		Ovary	Rucaparib		FDA guidelines
					BRCA1		Breast adenocarcinoma	Veliparib;Cisplatin		Early trials
					BRCA2		Ovary	[]		Early trials
					BRCA2		Cutaneous melanoma	[]		Case report
					BRCA2		Breast adenocarcinoma	[Olaparib]	Approved	Early trials
					BRCA2		Prostate adenocarcinoma	Olaparib	Approved	Early trials
					BRCA2		Ovary	Olaparib	Approved	FDA guidelines
					BRCA2		Breast adenocarcinoma	Platinum Agent		Early trials
					BRCA2		Ovary	Platinum Agent		Late trials
					BRCA2		Pancreas	Platinum Agent		Case report
					BRCA2		Ovary	Rucaparib		FDA guidelines
					BRCA2		Breast adenocarcinoma	Veliparib;Cisplatin		Early trials
chr11	119148891	T>C	Y371H	exon_8	CBL	ENST00000264033	Myelodisplasic proliferative syndrome	[]		Pre-clinical
chr11	119148930	T>C	C384R	exon_8	CBL	ENST00000264033	Myelodisplasic proliferative syndrome	[]		Pre-clinical
chr11	119148891	T>C	Y371H	exon_8	CBL	ENST00000264033	Myelodisplasic proliferative syndrome	Dasatinib		Pre-clinical
chr11	119148930	T>C	C384R	exon_8	CBL	ENST00000264033	Myelodisplasic proliferative syndrome	Dasatinib		Pre-clinical
					KRAS		Colorectal adenocarcinoma	Cetuximab	Approved	FDA guidelines
					KRAS		Non-small cell lung	[]		Pre-clinical
					KRAS		Stomach	[]		Pre-clinical
					CDH1		Breast adenocarcinoma	Bicalutamide		Pre-clinical
					CDK12		Ovary	[]		Pre-clinical
					CDK4		Liposarcoma;Lymphoma;Any cancer type	LEE011	Clinical Trials	Early trials
					CDK6		Liposarcoma;Lymphoma;Any cancer type	LEE011	Clinical Trials	Early trials
					CDKN1A		Any cancer type	[]		Pre-clinical
					CDKN1B		Any cancer type	[]		Pre-clinical
					CDKN2A		Cutaneous melanoma	[]		Case report
					CDKN2A		Glioma;Any cancer type	[]		Pre-clinical
					CDKN2A		Any cancer type	Ilorasertib	Clinical Trials	Early trials
					CDKN2B		Glioma;Any cancer type	[]		Pre-clinical
					CDKN2C		Glioma;Any cancer type	[]		Pre-clinical
					CHEK2		Prostate adenocarcinoma	Olaparib		Early trials
					MAP2K1		Cutaneous melanoma	[]		Early trials
					MAP2K1		Cutaneous melanoma	[]		Case report
					MAP2K1		Colorectal adenocarcinoma	[]		Case report
					MAP2K1		Any cancer type	[]		Pre-clinical
chr15	66729163	C>T	P124L	exon_3	MAP2K1	ENST00000307102	Cutaneous melanoma	[]		Case report
chr15	66727455	G>C	K57N	exon_2	MAP2K1	ENST00000307102	Cutaneous melanoma	[]		Case report
chr15	66729153	T>A	C121S	exon_3	MAP2K1	ENST00000307102	Cutaneous melanoma	[]		Case report
chr15	66727451	A>C	Q56P	exon_2	MAP2K1	ENST00000307102	Cutaneous melanoma	[]		Case report
chr15	66729162	C>T	P124S	exon_3	MAP2K1	ENST00000307102	Cutaneous melanoma	[]		Case report
chr15	66729163	C>T	P124L	exon_3	MAP2K1	ENST00000307102	Cutaneous melanoma	[]		Case report
chr5	149441328	A>C	Y571D	exon_12	CSF1R	ENST00000286301	Myelodisplasic proliferative syndrome	Imatinib		Pre-clinical
					CSF3R		Atypical chronic myeloid leukemia	Dasatinib		Pre-clinical
chr19	4117541	T>G	Q60P	exon_2	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Case report
chr3	41266109	C>T	H36Y	exon_3	CTNNB1	ENST00000349496	Endometrium	Everolimus;Letrozole		Early trials
chr3	41266113	C>G	S37C	exon_3	CTNNB1	ENST00000349496	Endometrium	Everolimus;Letrozole		Early trials
chr3	41266113	C>A	S37Y	exon_3	CTNNB1	ENST00000349496	Endometrium	Everolimus;Letrozole		Early trials
chr3	41266098	A>T	D32V	exon_3	CTNNB1	ENST00000349496	Endometrium	Everolimus;Letrozole		Early trials
chr19	4117617	C>T	V35M	exon_2	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Pre-clinical
chr19	4117584	G>A	L46F	exon_2	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Pre-clinical
chr19	4110581	T>C	N126D	exon_3	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Pre-clinical
chr19	4110584	A>T	C125S	exon_3	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Pre-clinical
chr1	162745497	A>T	I638F	exon_16	DDR2	ENST00000367922	Lung squamous cell	Dasatinib		Pre-clinical
chr1	162729630	T>G	L239R	exon_9	DDR2	ENST00000367922	Lung squamous cell	Dasatinib		Pre-clinical
chr1	162729671	G>T	G253C	exon_9	DDR2	ENST00000367922	Lung squamous cell	Dasatinib		Pre-clinical
chr1	162748407	G>T	G774V	exon_18	DDR2	ENST00000367922	Lung squamous cell	Dasatinib		Pre-clinical
chr1	162724415	C>G	L63V	exon_6	DDR2	ENST00000367922	Lung squamous cell	Dasatinib		Pre-clinical
chr1	162741822	G>A	G505S	exon_14	DDR2	ENST00000367922	Lung squamous cell	Dasatinib		Pre-clinical
chr1	162748390	T>G	S768R	exon_18	DDR2	ENST00000367922	Lung squamous cell	Dasatinib		Case report
chr1	162748390	T>G	S768R	exon_18	DDR2	ENST00000367922	Lung squamous cell	Erlotinib		Case report
					DNMT3A		Acute myeloid leukemia	Daunorubicin	Approved	FDA guidelines
					DPYD		Any cancer type	Capecitabine	Approved	FDA guidelines
chr1	97981343	A>C	I560S	exon_13	DPYD	ENST00000370192	Any cancer type	Capecitabine	Approved	FDA guidelines
chr1	97547947	T>A	D949V	exon_22	DPYD	ENST00000370192	Any cancer type	Capecitabine	Approved	FDA guidelines
					DPYD		Any cancer type	Flourouracil	Approved	FDA guidelines
chr1	97981343	A>C	I560S	exon_13	DPYD	ENST00000370192	Any cancer type	Flourouracil	Approved	FDA guidelines
chr1	97547947	T>A	D949V	exon_22	DPYD	ENST00000370192	Any cancer type	Flourouracil	Approved	FDA guidelines
					DPYD		Any cancer type	Tegafur	Approved	CPIC guidelines
chr1	97981343	A>C	I560S	exon_13	DPYD	ENST00000370192	Any cancer type	Tegafur	Approved	CPIC guidelines
chr1	97547947	T>A	D949V	exon_22	DPYD	ENST00000370192	Any cancer type	Tegafur	Approved	CPIC guidelines
chr19	4117541	T>G	Q60P	exon_2	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Case report
chr19	4117617	C>T	V35M	exon_2	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Pre-clinical
chr19	4117584	G>A	L46F	exon_2	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Pre-clinical
chr19	4110581	T>C	N126D	exon_3	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Pre-clinical
chr19	4110584	A>T	C125S	exon_3	MAP2K2	ENST00000262948	Cutaneous melanoma	[]		Pre-clinical
chr7	116423408	A>T	D1246V	exon_19	MET	ENST00000318493	Lung adenocarcinoma	[]		Case report
					NF1		Neuroblastoma	[]		Pre-clinical
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Lung	[]		Early trials
					EGFR		Lung	[]		Late trials
chr7	55259515	T>G	L858R	exon_21	EGFR	ENST00000275493	Lung	[]		Late trials
chr7	55259524	T>A	L861Q	exon_21	EGFR	ENST00000275493	Lung	[]		Late trials
chr7	55241708	G>C	G719A	exon_18	EGFR	ENST00000275493	Lung	[]		Late trials
chr7	55241707	G>A	G719S	exon_18	EGFR	ENST00000275493	Lung	[]		Late trials
chr7	55241707	G>T	G719C	exon_18	EGFR	ENST00000275493	Lung	[]		Late trials
chr7	55241708	G>A	G719D	exon_18	EGFR	ENST00000275493	Lung	[]		Late trials
chr7	55242470	T>C	L747S	exon_19	EGFR	ENST00000275493	Lung	[]		Late trials
chr7	55249005	G>T	S768I	exon_20	EGFR	ENST00000275493	Lung	[]		Late trials
chr7	55259524	T>C	L861P	exon_21	EGFR	ENST00000275493	Lung	[]		Late trials
chr7	55259524	T>G	L861R	exon_21	EGFR	ENST00000275493	Lung	[]		Late trials
					EGFR		Lung	[]		Early trials
					EGFR		Lung	[]		Case report
chr7	55259515	T>G	L858R	exon_21	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55259524	T>A	L861Q	exon_21	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55241708	G>C	G719A	exon_18	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55241707	G>A	G719S	exon_18	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55241707	G>T	G719C	exon_18	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55241708	G>A	G719D	exon_18	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55242470	T>C	L747S	exon_19	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55249005	G>T	S768I	exon_20	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55259524	T>C	L861P	exon_21	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55259524	T>G	L861R	exon_21	EGFR	ENST00000275493	Lung	[]		Early trials
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Lung	[]		Early trials
					EGFR		Lung	[]		Pre-clinical
chr7	55259515	T>G	L858R	exon_21	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55259524	T>A	L861Q	exon_21	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55241708	G>C	G719A	exon_18	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55241707	G>A	G719S	exon_18	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55241707	G>T	G719C	exon_18	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55241708	G>A	G719D	exon_18	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55242470	T>C	L747S	exon_19	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55249005	G>T	S768I	exon_20	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55259524	T>C	L861P	exon_21	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55259524	T>G	L861R	exon_21	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Lung	[]		Pre-clinical
chr7	55228009	C>G	S492R	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	[]		Early trials
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Non-small cell lung	[Rociletinib,HM61713]		Late trials
					EGFR		Non-small cell lung	Afatinib	Approved	FDA guidelines
					EGFR		Lung	Afatinib		Late trials
chr7	55259515	T>G	L858R	exon_21	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55259524	T>A	L861Q	exon_21	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55241708	G>C	G719A	exon_18	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55241707	G>A	G719S	exon_18	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55241707	G>T	G719C	exon_18	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55241708	G>A	G719D	exon_18	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55242470	T>C	L747S	exon_19	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55249005	G>T	S768I	exon_20	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55259524	T>C	L861P	exon_21	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55259524	T>G	L861R	exon_21	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	FDA guidelines
chr7	55259524	T>A	L861Q	exon_21	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	NCCN guidelines
chr7	55241708	G>C	G719A	exon_18	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	NCCN guidelines
chr7	55241707	G>A	G719S	exon_18	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	NCCN guidelines
chr7	55241707	G>T	G719C	exon_18	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	NCCN guidelines
chr7	55241708	G>A	G719D	exon_18	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	NCCN guidelines
chr7	55242470	T>C	L747S	exon_19	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	NCCN guidelines
chr7	55249005	G>T	S768I	exon_20	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	NCCN guidelines
chr7	55259524	T>C	L861P	exon_21	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	NCCN guidelines
chr7	55259524	T>G	L861R	exon_21	EGFR	ENST00000275493	Non-small cell lung	Afatinib	Approved	NCCN guidelines
					EGFR		Lung	Afatinib;Cetuximab		Early trials
chr7	55259515	T>G	L858R	exon_21	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55259524	T>A	L861Q	exon_21	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55241708	G>C	G719A	exon_18	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55241707	G>A	G719S	exon_18	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55241707	G>T	G719C	exon_18	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55241708	G>A	G719D	exon_18	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55242470	T>C	L747S	exon_19	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55249005	G>T	S768I	exon_20	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55259524	T>C	L861P	exon_21	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55259524	T>G	L861R	exon_21	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Lung	Afatinib;Cetuximab		Early trials
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Lung	Afatinib;Nimotuzumab		Early trials
chr7	55231430	C>T	P546S	exon_14	EGFR	ENST00000275493	Head an neck	Cetuximab		Case report
chr7	55242487	C>T	P753S	exon_19	EGFR	ENST00000275493	Head an neck	Cetuximab;Sirolimus		Case report
					EGFR		Non-small cell lung	Erlotinib	Approved	FDA guidelines
					EGFR		Lung	Erlotinib	Approved	Early trials
					EGFR		Lung	Erlotinib		Case report
chr7	55221822	C>T	A289V	exon_7	EGFR	ENST00000275493	Glioma	Erlotinib	Approved	Pre-clinical
chr7	55211080	G>A	R108K	exon_3	EGFR	ENST00000275493	Glioma	Erlotinib	Approved	Pre-clinical
chr7	55233043	G>T	G598V	exon_15	EGFR	ENST00000275493	Glioma	Erlotinib	Approved	Pre-clinical
chr7	55221743	A>C	T263P	exon_7	EGFR	ENST00000275493	Glioma	Erlotinib	Approved	Pre-clinical
					NRAS		Cutaneous melanoma	[]		Early trials
chr7	55242500	A>G	K757R	exon_19	EGFR	ENST00000275493	Lung	Erlotinib		Case report
chr7	55242467	A>G	E746G	exon_19	EGFR	ENST00000275493	Lung	Erlotinib		Case report
chr7	55259515	T>G	L858R	exon_21	EGFR	ENST00000275493	Non-small cell lung	Erlotinib	Approved	FDA guidelines
					EGFR		Non-small cell lung	Erlotinib	Approved	NCCN guidelines
chr3	178936091	G>T	E545*	exon_10	PIK3CA	ENST00000263967	Cutaneous melanoma	[]		Case report
					EGFR		Non-small cell lung	Gefitinib	Approved	FDA guidelines
					PIK3CA		Lung	[]		Early trials
chr7	55259515	T>G	L858R	exon_21	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55259524	T>A	L861Q	exon_21	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55241708	G>C	G719A	exon_18	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55241707	G>A	G719S	exon_18	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55241707	G>T	G719C	exon_18	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55241708	G>A	G719D	exon_18	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55242470	T>C	L747S	exon_19	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55249005	G>T	S768I	exon_20	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55259524	T>C	L861P	exon_21	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55259524	T>G	L861R	exon_21	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	FDA guidelines
chr7	55259524	T>A	L861Q	exon_21	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	NCCN guidelines
chr7	55241708	G>C	G719A	exon_18	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	NCCN guidelines
chr7	55241707	G>A	G719S	exon_18	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	NCCN guidelines
chr7	55241707	G>T	G719C	exon_18	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	NCCN guidelines
chr7	55241708	G>A	G719D	exon_18	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	NCCN guidelines
chr7	55242470	T>C	L747S	exon_19	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	NCCN guidelines
chr7	55249005	G>T	S768I	exon_20	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	NCCN guidelines
chr7	55259524	T>C	L861P	exon_21	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	NCCN guidelines
chr7	55259524	T>G	L861R	exon_21	EGFR	ENST00000275493	Non-small cell lung	Gefitinib	Approved	NCCN guidelines
chr3	138374245	C>A	D1067Y	exon_23	PIK3CB	ENST00000477593	Breast adenocarcinoma	[]		Case report
chr7	55241620	G>A	E690K	exon_18	EGFR	ENST00000275493	Endometrium	Lapatinib	Approved	Case report
					EGFR		Lung	Osimertinib	Approved	Early trials
					EGFR		Lung	Osimertinib		Pre-clinical
					PTEN		Colorectal adenocarcinoma	[]		Late trials
					PTEN		Endometrium	[]		Early trials
chr7	55259515	T>G	L858R	exon_21	EGFR	ENST00000275493	Lung	Osimertinib	Approved	Early trials
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Non-small cell lung	Osimertinib	Approved	FDA guidelines
chr7	55228009	C>G	S492R	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	Panitumumab		Case report
					EGFR		Glioblastoma	Rindopepimut	Clinical Trials	Late trials
chr1	16464489	C>T	G391R	exon_5	EPHA2	ENST00000358432	Lung squamous cell	[]		Pre-clinical
chr1	16464489	C>T	G391R	exon_5	EPHA2	ENST00000358432	Lung squamous cell	[]		Pre-clinical
chr1	16464489	C>T	G391R	exon_5	EPHA2	ENST00000358432	Lung squamous cell	Dasatinib		Pre-clinical
chr1	16464489	C>T	G391R	exon_5	EPHA2	ENST00000358432	Lung squamous cell	Dasatinib		Pre-clinical
					ERBB2		Lung adenocarcinoma	[Afatinib,Lapatinib,Neratinib]		Early trials
					ERBB2		Lung adenocarcinoma	[Trastuzumab]		Early trials
					ERBB2		Lung	Ado-Trastuzumab Emtansine		Early trials
chr17	37879601	TT>AG	V659E	exon_17	ERBB2	ENST00000269571	Lung	Ado-Trastuzumab Emtansine		Early trials
chr17	37868208	C>T	S310F	exon_8	ERBB2	ENST00000269571	Lung	Ado-Trastuzumab Emtansine		Early trials
					ERBB2		Lung adenocarcinoma	Afatinib		Early trials
chr17	37881064	C>T	T798I	exon_20	ERBB2	ENST00000269571	Breast adenocarcinoma	Afatinib		Pre-clinical
					ERBB2		Non-small cell lung	Dacomitinib		Early trials
chr17	37880261	G>T	D769Y	exon_19	ERBB2	ENST00000269571	Breast adenocarcinoma	Lapatinib		Pre-clinical
chr17	37880261	G>C	D769H	exon_19	ERBB2	ENST00000269571	Breast adenocarcinoma	Lapatinib		Pre-clinical
chr17	37881616	C>T	R896C	exon_22	ERBB2	ENST00000269571	Breast adenocarcinoma	Lapatinib		Pre-clinical
chr17	37881000	G>C	V777L	exon_20	ERBB2	ENST00000269571	Breast adenocarcinoma	Lapatinib		Pre-clinical
chr17	37881332	G>A	V842I	exon_21	ERBB2	ENST00000269571	Breast adenocarcinoma	Lapatinib		Pre-clinical
chr17	37868205	G>C	G309A	exon_8	ERBB2	ENST00000269571	Breast adenocarcinoma	Lapatinib		Pre-clinical
chr17	37879601	TT>AG	V659E	exon_17	ERBB2	ENST00000269571	Breast adenocarcinoma;Lung adenocarcinoma	Lapatinib		Case report
					ERBB2		Lung adenocarcinoma	Lapatinib		Early trials
					ERBB2		Breast adenocarcinoma	Neratinib		Pre-clinical
					ERBB2		Lung adenocarcinoma	Neratinib		Early trials
chr17	37880213	A>G	K753E	exon_19	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Pre-clinical
chr17	37880220	T>C	L755S	exon_19	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Pre-clinical
chr17	37868205	G>C	G309A	exon_8	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Pre-clinical
chr17	37880261	G>T	D769Y	exon_19	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Pre-clinical
chr17	37880261	G>C	D769H	exon_19	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Pre-clinical
chr17	37881616	C>T	R896C	exon_22	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Pre-clinical
chr17	37881000	G>C	V777L	exon_20	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Pre-clinical
chr17	37881332	G>A	V842I	exon_21	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Pre-clinical
					ERBB2		Lung adenocarcinoma	Neratinib		Early trials
chr17	37881414	T>G	L869R	exon_21	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Case report
					ERBB2		Any cancer type	Neratinib		Early trials
					ERBB2		Any cancer type	Neratinib		Early trials
					ERBB2		Lung adenocarcinoma	Tensirolimus		Early trials
					STK11		Lung	[]		Pre-clinical
chr17	37880261	G>T	D769Y	exon_19	ERBB2	ENST00000269571	Breast adenocarcinoma;Any cancer type	Trastuzumab		Pre-clinical
chr17	37880261	G>C	D769H	exon_19	ERBB2	ENST00000269571	Breast adenocarcinoma;Any cancer type	Trastuzumab		Pre-clinical
chr17	37881616	C>T	R896C	exon_22	ERBB2	ENST00000269571	Breast adenocarcinoma;Any cancer type	Trastuzumab		Pre-clinical
chr17	37868205	G>A	G309E	exon_8	ERBB2	ENST00000269571	Breast adenocarcinoma;Any cancer type	Trastuzumab		Pre-clinical
chr17	37868208	C>T	S310F	exon_8	ERBB2	ENST00000269571	Breast adenocarcinoma;Any cancer type	Trastuzumab		Pre-clinical
chr17	37868208	C>A	S310Y	exon_8	ERBB2	ENST00000269571	Breast adenocarcinoma;Any cancer type	Trastuzumab		Pre-clinical
chr17	37868210	T>C	C311R	exon_8	ERBB2	ENST00000269571	Breast adenocarcinoma;Any cancer type	Trastuzumab		Pre-clinical
chr17	37868205	G>A	G309E	exon_8	ERBB2	ENST00000269571	Any cancer type	Trastuzumab		Pre-clinical
chr17	37868208	C>T	S310F	exon_8	ERBB2	ENST00000269571	Any cancer type	Trastuzumab		Pre-clinical
chr17	37868208	C>A	S310Y	exon_8	ERBB2	ENST00000269571	Any cancer type	Trastuzumab		Pre-clinical
chr17	37868210	T>C	C311R	exon_8	ERBB2	ENST00000269571	Any cancer type	Trastuzumab		Pre-clinical
chr17	37868241	A>G	E321G	exon_8	ERBB2	ENST00000269571	Any cancer type	Trastuzumab		Pre-clinical
chr17	37868279	T>A	C334S	exon_8	ERBB2	ENST00000269571	Any cancer type	Trastuzumab		Pre-clinical
chr17	37880997	GG>CT	G776L	exon_20	ERBB2	ENST00000269571	Lung adenocarcinoma	Trastuzumab		Case report
					ERBB2		Lung adenocarcinoma	Trastuzumab		Early trials
chr12	56481857	C>A	P262H	exon_7	ERBB3	ENST00000267101	Any cancer type	[]		Pre-clinical
chr12	56481922	G>A	G284R	exon_7	ERBB3	ENST00000267101	Any cancer type	[]		Pre-clinical
chr12	56481857	C>A	P262H	exon_7	ERBB3	ENST00000267101	Any cancer type	[]		Pre-clinical
chr12	56481922	G>A	G284R	exon_7	ERBB3	ENST00000267101	Any cancer type	[]		Pre-clinical
chr12	56490980	A>G	Q809R	exon_20	ERBB3	ENST00000267101	Any cancer type	[]		Pre-clinical
chr12	56481922	G>A	G284R	exon_7	ERBB3	ENST00000267101	Bladder	Afatinib		Case report
chr12	56478851	C>G	R103G	exon_3	ERBB3	ENST00000267101	Bladder	Afatinib		Case report
chr12	56481922	G>A	G284R	exon_7	ERBB3	ENST00000267101	Bladder	Afatinib		Case report
chr12	56478854	G>A	V104M	exon_3	ERBB3	ENST00000267101	Bladder	Afatinib		Case report
chr12	56478851	C>G	R103G	exon_3	ERBB3	ENST00000267101	Bladder	Afatinib		Case report
chr12	56481857	C>A	P262H	exon_7	ERBB3	ENST00000267101	Any cancer type	Lapatinib		Pre-clinical
chr12	56481922	G>A	G284R	exon_7	ERBB3	ENST00000267101	Any cancer type	Lapatinib		Pre-clinical
chr12	56490980	A>G	Q809R	exon_20	ERBB3	ENST00000267101	Any cancer type	Lapatinib		Pre-clinical
chr12	56481857	C>A	P262H	exon_7	ERBB3	ENST00000267101	Any cancer type	Pertuzumab		Pre-clinical
chr12	56481922	G>A	G284R	exon_7	ERBB3	ENST00000267101	Any cancer type	Pertuzumab		Pre-clinical
chr12	56481857	C>A	P262H	exon_7	ERBB3	ENST00000267101	Any cancer type	Trastuzumab		Pre-clinical
chr12	56481922	G>A	G284R	exon_7	ERBB3	ENST00000267101	Any cancer type	Trastuzumab		Pre-clinical
chr12	56490980	A>G	Q809R	exon_20	ERBB3	ENST00000267101	Any cancer type	Trastuzumab		Pre-clinical
chr2	212578308	C>T	E317K	exon_8	ERBB4	ENST00000342788	Cutaneous melanoma	Lapatinib		Pre-clinical
chr2	212566827	C>T	E452K	exon_12	ERBB4	ENST00000342788	Cutaneous melanoma	Lapatinib		Pre-clinical
chr2	212537975	G>A	R544W	exon_14	ERBB4	ENST00000342788	Cutaneous melanoma	Lapatinib		Pre-clinical
chr2	212570064	G>A	R393W	exon_10	ERBB4	ENST00000342788	Cutaneous melanoma	Lapatinib		Pre-clinical
chr2	212295699	C>T	E872K	exon_21	ERBB4	ENST00000342788	Cutaneous melanoma	Lapatinib		Pre-clinical
					ERCC1		Lung	[]		Pre-clinical
					ERCC1		Lung	Cisplatin		Pre-clinical
					TP53		Liposarcoma	[]		Early trials
					ERCC2		Bladder	Cisplatin		Early trials
					ERCC4		Ovary	Cisplatin		Pre-clinical
					ERCC6		Ovary	Cisplatin		Pre-clinical
					ESR1		Breast adenocarcinoma	[GDC-0810]		Case report
chr1	156846342	G>A	G595R	exon_14	NTRK1	ENST00000524377	Colorectal adenocarcinoma	[Entrectinib]		Case report
chr1	156849107	G>T	G667C	exon_15	NTRK1	ENST00000524377	Colorectal adenocarcinoma	[Entrectinib]		Case report
					ESR1		Breast adenocarcinoma	Fluvestrant		Late trials
chr2	212426689	TG>CC	H809G	exon_20	ERBB4	ENST00000342788	Breast adenocarcinoma	[Lapatinib]		Case report
chr9	133748283	C>T	T315I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	[Nilotinib,Dasatinib]	Approved	European LeukemiaNet guidelines
					EZH2		Lymphoma	[EPZ-005687,EPZ-6438]	Pre-clinical	Pre-clinical
					FANCA		Prostate adenocarcinoma	Olaparib		Case report
					FANCC		Bladder	Cisplatin	Approved	Early trials
					FAT1		Head an neck squamous	[]		Pre-clinical
					FBXW7		Acute lymphoblastic leukemia	[]		Late trials
					TP53		Breast adenocarcinoma	Abemaciclib		Early trials
chrX	66931463	T>A	L702H	exon_4	AR	ENST00000374690	Prostate adenocarcinoma	Abiraterone	Approved	Early trials
chrX	66943552	A>G	T878A	exon_8	AR	ENST00000374690	Prostate adenocarcinoma	Abiraterone	Approved	Early trials
					FGFR2		Lung	[]		Pre-clinical
chr10	123279677	G>C	S252W	exon_7	FGFR2	ENST00000457416	Endometrium	[]		Pre-clinical
chr10	123258034	A>C	N550K	exon_12	FGFR2	ENST00000457416	Endometrium	[]		Pre-clinical
chr10	123256219	C>T	V565I	exon_13	FGFR2	ENST00000457416	Endometrium	[]		Pre-clinical
chr10	123279562	C>A	W290C	exon_7	FGFR2	ENST00000457416	Lung squamous cell	[]		Pre-clinical
chr10	123278324	G>C	S320C	exon_8	FGFR2	ENST00000457416	Lung squamous cell	[]		Pre-clinical
chr10	123247514	C>G	K660N	exon_14	FGFR2	ENST00000457416	Lung squamous cell	[]		Pre-clinical
chr2	29445213	A>G	I1171T	exon_22	ALK	ENST00000389048	Lung adenocarcinoma	Alectinib		Case report
					FGFR2		Endometrium	Ponatinib		Pre-clinical
					FGFR3		Bladder	[]		Early trials
					FGFR3		Myeloma	[]		Pre-clinical
chr4	1803568	C>G	S249C	exon_7	FGFR3	ENST00000440486	Lung adenocarcinoma	[]		Pre-clinical
chr4	1808313	G>A	G691R	exon_16	FGFR3	ENST00000440486	Lung adenocarcinoma	[]		Pre-clinical
chrX	66943549	T>C	F877L	exon_8	AR	ENST00000374690	Prostate adenocarcinoma	Arn-509		Case report
					FGFR3		Myeloma	Bortezomib		Pre-clinical
					FGFR4		Rhabdomyosarcoma	[]		Pre-clinical
					FLCN		Renal	Everolimus		Case report
chr4	1806099	A>G	Y373C	exon_9	FGFR3	ENST00000440486	Myeloma	Bortezomib		Pre-clinical
					FLT3		Acute myeloid leukemia	[]		Early trials
					FLT3		Acute myeloid leukemia	[]		Pre-clinical
					FLT3		Acute myeloid leukemia	Crenolanib		Pre-clinical
					FLT3		Acute myeloid leukemia	Lestaurtinib		Case report
					FLT3		Acute myeloid leukemia	Midostaurin		Case report
					FLT3		Acute myeloid leukemia	Midostaurin		Pre-clinical
chr9	133748283	C>T	T315I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Bosutinib	Approved	European LeukemiaNet guidelines
					FLT3		Acute myeloid leukemia	Quizartinib		Early trials
					FLT3		Acute myeloid leukemia	Sorafenib		Early trials
					FLT3		Acute myeloid leukemia	Sorafenib;Azacytidine		Early trials
					NF1		Plexiform neurofibroma	Cediranib		Early trials
chr2	29445466	C>T	G1123S	exon_21	ALK	ENST00000389048	Lung adenocarcinoma	Ceritinib		Case report
chrX	153762634	G>A	S218F	exon_6	G6PD	ENST00000393562	Any cancer type	Dabrafenib	Approved	FDA guidelines
					GATA3		Breast adenocarcinoma	[]		Pre-clinical
chr6	117639399	G>T	S1986Y	exon_37	ROS1	ENST00000368508	Lung adenocarcinoma	Ceritinib		Case report
chr6	117639399	G>A	S1986F	exon_37	ROS1	ENST00000368508	Lung adenocarcinoma	Ceritinib		Case report
chr19	3118942	A>T	Q209L	exon_5	GNA11	ENST00000078429	Cutaneous melanoma	[]		Pre-clinical
chr19	3118942	A>C	Q209P	exon_5	GNA11	ENST00000078429	Cutaneous melanoma	[]		Pre-clinical
chr19	3118942	A>T	Q209L	exon_5	GNA11	ENST00000078429	Cutaneous melanoma	Selumetinib		Early trials
chr19	3118942	A>C	Q209P	exon_5	GNA11	ENST00000078429	Cutaneous melanoma	Selumetinib		Early trials
chr19	3118942	A>T	Q209L	exon_5	GNA11	ENST00000078429	Cutaneous melanoma	Vorinostat		Pre-clinical
chr19	3118942	A>C	Q209P	exon_5	GNA11	ENST00000078429	Cutaneous melanoma	Vorinostat		Pre-clinical
					GNAQ		Cutaneous melanoma	[]		Pre-clinical
					GNAQ		Cutaneous melanoma	[]		Pre-clinical
					GNAQ		Cutaneous melanoma	[]		Pre-clinical
					GNAQ		Cutaneous melanoma	Selumetinib		Early trials
					GNAS		Any cancer type	[]		Pre-clinical
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Colorectal adenocarcinoma	Cetuximab		Late trials
					HRAS		Acute myeloid leukemia	[]		Pre-clinical
					HRAS		Cervix squamous cell	[]		Pre-clinical
					HRAS		Cervix	[]		Pre-clinical
					HRAS		Any cancer type	Tipifarnib		Early trials
					HRAS		Any cancer type	Tipifarnib	Clinical Trials	Early trials
					IDH1		Acute myeloid leukemia	[]		Pre-clinical
					IDH1		Acute myeloid leukemia	[]		Early trials
					IDH1		Any cancer type	[]		Pre-clinical
					IDH1		Glioma	AG-120	Clinical Trials	Early trials
					IDH1		Cholangiocarcinoma	Dasatinib	Clinical Trials	Early trials
					IDH1		Billiary tract	Dasatinib		Pre-clinical
					IDH1		Acute myeloid leukemia	Venetoclax		Early trials
chr15	90631934	CG>TT	R140K	exon_4	IDH2	ENST00000330062	Hematologic malignancies	AG-221	Clinical Trials	Early trials
chr15	90631838	C>T	R172K	exon_4	IDH2	ENST00000330062	Hematologic malignancies	AG-221	Clinical Trials	Early trials
					IDH2		Cholangiocarcinoma	Dasatinib	Clinical Trials	Early trials
					IDH2		Billiary tract	Dasatinib		Pre-clinical
					IDH2		Acute myeloid leukemia	Venetoclax		Early trials
chr7	55227924	C>T	S464L	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	Cetuximab	Approved	Pre-clinical
chr7	55227926	G>A	G465R	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	Cetuximab	Approved	Pre-clinical
chr7	55228006	A>G	I491M	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	Cetuximab	Approved	Pre-clinical
chr7	55228009	C>G	S492R	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	Cetuximab		Case report
chr7	55227926	G>A	G465R	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	Cetuximab		Case report
chr7	55227884	C>T	R451C	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	Cetuximab		Case report
chr7	55227933	A>C	K467T	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	Cetuximab		Case report
					INPP4B		Breast adenocarcinoma	[]		Pre-clinical
					KRAS		Any cancer type	[]		Pre-clinical
					KRAS		Endometrium	[]		Pre-clinical
					JAK1		Acute lymphoblastic leukemia	Ruxolitinib		Pre-clinical
chr9	5073770	G>T	V617F	exon_14	JAK2	ENST00000381652	Acute myeloid leukemia	[]		Pre-clinical
					NRAS		Colorectal adenocarcinoma	Panitumumab	Approved	FDA guidelines
chr9	5073770	G>T	V617F	exon_14	JAK2	ENST00000381652	Acute myeloid leukemia	Ruxolitinib		Early trials
chr9	5073770	G>T	V617F	exon_14	JAK2	ENST00000381652	Myelofibrosis	Ruxolitinib	Approved	FDA guidelines
chr19	17948009	G>A	A572V	exon_13	JAK3	ENST00000458235	Lymphoma	[]		Pre-clinical
chr19	17948006	G>A	A573V	exon_13	JAK3	ENST00000458235	Lymphoma	[]		Pre-clinical
chr19	17945969	C>T	R657Q	exon_15	JAK3	ENST00000458235	Megakaryoblastic leukemia	[]		Pre-clinical
chr19	17954634	A>G	I87T	exon_3	JAK3	ENST00000458235	Megakaryoblastic leukemia	[]		Pre-clinical
chr19	17949138	C>A	Q501H	exon_11	JAK3	ENST00000458235	Megakaryoblastic leukemia	[]		Pre-clinical
chr11	128781671	T>G	L168R	exon_2	KCNJ5	ENST00000529694	Adrenal adenoma	Amiloride	Approved	Pre-clinical
chr11	128781671	T>G	L168R	exon_2	KCNJ5	ENST00000529694	Adrenal adenoma	Verapamil	Approved	Pre-clinical
chr4	55955969	C>T	A1065T	exon_24	KDR	ENST00000263923	Any cancer type	[]		Pre-clinical
					KIT		Gastrointestinal stromal	[]		Early trials
					KIT		Gastrointestinal stromal	[]		Pre-clinical
					KIT		Gastrointestinal stromal	Dasatinib		Pre-clinical
					KIT		Cutaneous melanoma	Dasatinib		Case report
chr4	55599321	A>T	D816V	exon_17	KIT	ENST00000288135	Systemic mastocytosis	Dasatinib		Early trials
chr4	55599321	A>T	D816V	exon_17	KIT	ENST00000288135	Acute myeloid leukemia	Dasatinib		Case report
chr4	55599320	G>T	D816Y	exon_17	KIT	ENST00000288135	Any cancer type	Dasatinib		Pre-clinical
chr4	55599320	GA>TT	D816F	exon_17	KIT	ENST00000288135	Any cancer type	Dasatinib		Pre-clinical
chr4	55599321	A>T	D816V	exon_17	KIT	ENST00000288135	Any cancer type	Dasatinib		Pre-clinical
chr4	55599340	T>G	N822K	exon_17	KIT	ENST00000288135	Acute myeloid leukemia	Dasatinib		Pre-clinical
					KIT		Acute myeloid leukemia	Imatinib		Pre-clinical
					KIT		Thymic	Imatinib		Case report
					PIK3CA		Colorectal adenocarcinoma	Cetuximab		Late trials
					KIT		Gastrointestinal stromal	Imatinib	Approved	FDA guidelines
					KIT		Cutaneous melanoma	Imatinib		Late trials
					KIT		Cutaneous melanoma	Imatinib	Approved	NCCN guidelines
					TP53		Female germ cell tumor;Male germ cell tumor	Cisplatin		Early trials
					ALK		Lung adenocarcinoma	Crizotinib		Case report
chr4	55599332	G>T	D820Y	exon_17	KIT	ENST00000288135	Cutaneous melanoma	Imatinib		Case report
					ALK		Non-small cell lung	Crizotinib	Approved	Clinical trials
chr4	55593591	T>A	Y553N	exon_11	KIT	ENST00000288135	Thymic	Imatinib		Case report
					KIT		Cutaneous melanoma	Nilotinib		Early trials
					KIT		Gastrointestinal stromal	Nilotinib		Early trials
chr4	55599332	G>T	D820Y	exon_17	KIT	ENST00000288135	Cutaneous melanoma	Nilotinib		Case report
					KIT		Gastrointestinal stromal	Ponatinib		Early trials
chr4	55602664	G>C	A829P	exon_18	KIT	ENST00000288135	Gastrointestinal stromal	Ponatinib		Pre-clinical
chr4	55594258	T>C	V654A	exon_13	KIT	ENST00000288135	Gastrointestinal stromal	Ponatinib		Pre-clinical
chr4	55595519	C>T	T670I	exon_14	KIT	ENST00000288135	Gastrointestinal stromal	Ponatinib		Pre-clinical
					KIT		Gastrointestinal stromal	Regorafenib	Approved	FDA guidelines
					KIT		Thymic	Sorafenib		Case report
					KIT		Gastrointestinal stromal	Sorafenib		Early trials
					KIT		Gastrointestinal stromal	Sorafenib		Early trials
					KIT		Cutaneous melanoma	Sorafenib		Case report
					KIT		Gastrointestinal stromal	Sorafenib		Pre-clinical
chr4	55599334	T>G	D820E	exon_17	KIT	ENST00000288135	Thymic	Sorafenib		Case report
					KIT		Gastrointestinal stromal	Sunitinib		Late trials
					KIT		Gastrointestinal stromal	Sunitinib	Approved	FDA guidelines
					KIT		Cutaneous melanoma	Sunitinib		Late trials
chr2	29445258	C>T	C1156Y	exon_22	ALK	ENST00000389048	Non-small cell lung	Crizotinib	Approved	Case report
chr2	29443631	G>T	L1196M	exon_23	ALK	ENST00000389048	Non-small cell lung	Crizotinib	Approved	Case report
chr2	29443697	A>G	F1174L	exon_23	ALK	ENST00000389048	Glioma	Crizotinib		Pre-clinical
chr4	55595599	C>T	H697Y	exon_14	KIT	ENST00000288135	Thymic	Sunitinib		Pre-clinical
chr4	55595599	C>T	H697Y	exon_14	KIT	ENST00000288135	Thymic	Sunitinib		Pre-clinical
chr4	55593591	T>A	Y553N	exon_11	KIT	ENST00000288135	Thymic	Sunitinib		Case report
					KRAS		Colorectal adenocarcinoma	Panitumumab	Approved	FDA guidelines
					KRAS		Gastrointestinal stromal	Imatinib		Case report
					KRAS		Colorectal adenocarcinoma	Panitumumab		NCCN guidelines
					KRAS		Colorectal adenocarcinoma	Cetuximab		NCCN guidelines
chr2	29443631	G>T	L1196M	exon_23	ALK	ENST00000389048	Lung adenocarcinoma	Crizotinib		Case report
chr2	29445270	A>C	L1152R	exon_22	ALK	ENST00000389048	Lung adenocarcinoma	Crizotinib		Case report
chr2	29445258	C>T	C1156Y	exon_22	ALK	ENST00000389048	Lung adenocarcinoma	Crizotinib		Case report
chr2	29443697	A>G	F1174L	exon_23	ALK	ENST00000389048	Lung adenocarcinoma	Crizotinib		Case report
chr2	29443613	C>T	G1202R	exon_23	ALK	ENST00000389048	Lung adenocarcinoma	Crizotinib		Case report
chr2	29443600	G>T	S1206Y	exon_23	ALK	ENST00000389048	Lung adenocarcinoma	Crizotinib		Case report
chr2	29432682	C>G	G1269A	exon_25	ALK	ENST00000389048	Lung adenocarcinoma	Crizotinib		Case report
chr2	29445213	A>G	I1171T	exon_22	ALK	ENST00000389048	Lung adenocarcinoma	Crizotinib		Case report
					MET		Any cancer type	Crizotinib		Pre-clinical
					KRAS		Lung	[]		NCCN guidelines
					KRAS		Colorectal adenocarcinoma	Trastuzumab;Lapatinib		Late trials
chr6	117638347	C>T	G2032R	exon_38	ROS1	ENST00000368508	Lung adenocarcinoma	Crizotinib	Approved	Case report
chr6	117639399	G>T	S1986Y	exon_37	ROS1	ENST00000368508	Lung adenocarcinoma	Crizotinib		Case report
chr6	117639399	G>A	S1986F	exon_37	ROS1	ENST00000368508	Lung adenocarcinoma	Crizotinib		Case report
					KRAS		Lung	[]		Pre-clinical
					KRAS		Lung	[]		Pre-clinical
					KRAS		Lung	[]		Early trials
					KRAS		Cervix squamous cell	[]		Pre-clinical
					KRAS		Colorectal adenocarcinoma	[]		Pre-clinical
					KRAS		Colorectal adenocarcinoma	[]		Pre-clinical
					KRAS		Lung	[]		Pre-clinical
					KRAS		Lung	[]		Case report
					KRAS		Lung	[]		Case report
					KRAS		Lung	[]		Pre-clinical
					KRAS		Lung	[]		Pre-clinical
					KRAS		Colorectal adenocarcinoma	[]		Pre-clinical
					KRAS		Colorectal adenocarcinoma	[]		Pre-clinical
					KRAS		Colorectal adenocarcinoma	[]		Pre-clinical
chr9	133747588	G>C	V299L	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	European LeukemiaNet guidelines
chr9	133748282	A>G	T315A	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	European LeukemiaNet guidelines
chr9	133748288	T>C	F317L	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	European LeukemiaNet guidelines
chr9	133748288	T>G	F317V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	European LeukemiaNet guidelines
chr9	133748288	T>A	F317I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	European LeukemiaNet guidelines
chr9	133748289	T>G	F317C	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Dasatinib	Approved	European LeukemiaNet guidelines
					KRAS		Lung;Billiary tract	[]		Early trials
					KRAS		Acute myeloid leukemia;Cervix;Ovary	[]		Pre-clinical
					NF1		Lung	Dasatinib		Pre-clinical
					KRAS		Acute lymphoblastic leukemia	[]		Pre-clinical
					FGFR2		Endometrium	Dovitinib		Pre-clinical
					KRAS		Colorectal adenocarcinoma	[]		Pre-clinical
					KRAS		Lung	[]		Early trials
chrX	66943549	T>C	F877L	exon_8	AR	ENST00000374690	Prostate adenocarcinoma	Enzalutamide		Case report
					KRAS		Endometrium	[]		Case report
					KRAS		Endometrium	[]		Pre-clinical
					KRAS		Lung	[]		Early trials
					EGFR		Lung	Erlotinib		Case report
					KRAS		Lung	Abemaciclib		Early trials
					NF1		Lung	Erlotinib		Pre-clinical
					NF2		Schwannoma	Erlotinib		Early trials
chr1	11187096	A>G	F2108L	exon_45	MTOR	ENST00000361445	Thyroid carcinoma	Everolimus		Case report
					MAP2K1		Any cancer type	[]		Pre-clinical
					MAP2K1		Cutaneous melanoma	[]		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	Everolimus		Early trials
					NF1		Malignant peripheral nerve sheat tumor	Everolimus;Bevacizumab		Early trials
chr15	66729153	T>A	C121S	exon_3	MAP2K1	ENST00000307102	Cutaneous melanoma	[]		Pre-clinical
chr15	66727454	A>C	K57T	exon_2	MAP2K1	ENST00000307102	Colorectal adenocarcinoma	Panitumumab;Trametinib		Case report
					MAP2K1		Ovary	Selumetinib		Case report
chr15	66727451	A>C	Q56P	exon_2	MAP2K1	ENST00000307102	Any cancer type	Trametinib		Pre-clinical
					NF1		Glioma	Everolimus;Erlotinib		Case report
					ESR1		Breast adenocarcinoma	Exemestane		Late trials
chrX	66943552	A>G	T878A	exon_8	AR	ENST00000374690	Prostate adenocarcinoma	Flutamide		Case report
chr6	152419923	A>C	Y537S	exon_10	ESR1	ENST00000440973	Breast adenocarcinoma	Fulvestrant		Pre-clinical
					EGFR		Head an neck	Gefitinib	Approved	Case report
					MET		Renal	Savolitinib		Early trials
chr7	55259469	G>A	V843I	exon_21	EGFR	ENST00000275493	Head an neck	Gefitinib	Approved	Case report
					SLC29A1		Bladder	Gemcitabine		Pre-clinical
					BTK		Mantle cell lymphoma	Ibrutinib		Case report
chr7	116417464	A>G	H1112R	exon_16	MET	ENST00000318493	Renal	[]		Early trials
chr7	116423474	T>C	M1268T	exon_19	MET	ENST00000318493	Renal	[]		Case report
chr7	116417464	A>T	H1112L	exon_16	MET	ENST00000318493	Any cancer type	[Crizotinib]		Pre-clinical
					MET		Renal	Crizotinib		Early trials
chr7	116417457	G>A	V1110I	exon_16	MET	ENST00000318493	Any cancer type	Crizotinib		Pre-clinical
chr7	116417464	A>G	H1112R	exon_16	MET	ENST00000318493	Any cancer type	Crizotinib		Pre-clinical
chr7	116423474	T>C	M1268T	exon_19	MET	ENST00000318493	Any cancer type	Crizotinib		Pre-clinical
chr7	116411923	C>T	R988C	exon_14	MET	ENST00000318493	Any cancer type	Crizotinib		Pre-clinical
chr7	116411990	C>T	T1010I	exon_14	MET	ENST00000318493	Any cancer type	Crizotinib		Pre-clinical
chrX	100611165	A>T	C481S	exon_15	BTK	ENST00000308731	Chronic lymphocytic leukemia	Ibrutinib		Early trials
chr16	81946260	C>T	R665W	exon_19	PLCG2	ENST00000359376	Chronic lymphocytic leukemia	Ibrutinib	Approved	Early trials
chr16	81962183	A>T	L845F	exon_24	PLCG2	ENST00000359376	Chronic lymphocytic leukemia	Ibrutinib	Approved	Early trials
chr9	133738325	T>C	I242T	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738330	A>G	M244V	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738340	A>G	K247R	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738342	C>G	L248V	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738349	G>A	G250E	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738348	G>A	G250R	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738355	A>G	Q252R	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738356	G>T	Q252H	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738358	A>T	Y253F	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738357	T>C	Y253H	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738363	G>A	E255K	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738364	A>T	E255V	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738309	A>G	M237V	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738374	G>C	E258D	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738382	G>T	W261L	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133738417	T>A	L273M	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747516	G>A	E275K	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747516	G>C	E275Q	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747520	A>G	D276G	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747522	A>G	T277A	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747528	G>A	E279K	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747532	T>C	V280A	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747559	T>C	V289A	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747558	G>A	V289I	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747568	A>T	E292V	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747567	G>C	E292Q	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747570	A>G	I293V	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747585	C>G	L298V	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133747588	G>C	V299L	exon_5	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748270	T>C	F311L	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748270	T>A	F311I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748283	C>T	T315I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748288	T>C	F317L	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748288	T>G	F317V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748288	T>A	F317I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748289	T>G	F317C	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748298	A>G	Y320C	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748310	T>A	L324Q	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748363	T>C	Y342H	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748367	T>C	M343T	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748370	C>T	A344V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748388	C>T	A350V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748391	T>C	M351T	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748404	G>C	E355D	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748403	A>G	E355G	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748403	A>C	E355A	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748414	T>G	F359V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748414	T>A	F359I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748415	T>G	F359C	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133748414	T>C	F359L	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750256	G>T	D363Y	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750259	C>A	L364I	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750263	C>T	A365V	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750266	C>G	A366G	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750278	T>C	L370P	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750281	T>C	V371A	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750286	G>A	E373K	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750304	G>A	V379I	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750307	G>A	A380T	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750313	T>C	F382L	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750319	C>A	L384M	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750328	T>A	L387M	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750330	G>T	L387F	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750328	T>G	L387V	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750331	A>C	M388L	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750347	A>G	Y393C	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750356	A>C	H396P	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750356	A>G	H396R	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750355	CA>GC	H396A	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750358	G>C	A397P	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750419	C>T	S417F	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750419	C>A	S417Y	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750422	T>G	I418S	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133750421	A>G	I418V	exon_7	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753828	G>A	A433T	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753844	C>G	S438C	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753879	G>A	E450K	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753880	A>G	E450G	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753880	A>C	E450A	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753880	A>T	E450V	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753888	G>A	E453K	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753889	A>G	E453G	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753889	A>C	E453A	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753889	A>T	E453V	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753906	G>A	E459K	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753907	A>G	E459G	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753907	A>C	E459A	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753907	A>T	E459V	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133753947	G>C	M472I	exon_8	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133755470	C>T	P480L	exon_9	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133755488	T>C	F486S	exon_9	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
chr9	133755893	A>G	E507G	exon_10	ABL1	ENST00000318560	Chronic myeloid leukemia	Imatinib	Approved	European LeukemiaNet guidelines
					KIT		Gastrointestinal stromal	Imatinib		Late trials
					KIT		Gastrointestinal stromal	Imatinib		Late trials
					KIT		Gastrointestinal stromal	Imatinib		Pre-clinical
					KIT		Cutaneous melanoma	Imatinib		Early trials
					KIT		Gastrointestinal stromal;Myelodisplasic syndrome;Myelodisplasic proliferative syndrome;Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia;Chronic myeloid leukemia;Acute lymphoblastic leukemia;Systemic mastocytosis	Imatinib	Approved	FDA guidelines
chr4	55595519	C>T	T670I	exon_14	KIT	ENST00000288135	Gastrointestinal stromal	Imatinib		Case report
					MLL2		Lung squamous cell	Bicalutamide		Pre-clinical
chr1	43815009	GG>TT	W515F	exon_10	MPL	ENST00000372470	Myelodisplasic proliferative syndrome	[]		Pre-clinical
					MSH3		Any cancer type	[]		Pre-clinical
chr1	11187096	A>G	F2108L	exon_45	MTOR	ENST00000361445	Any cancer type	[]		Pre-clinical
chr1	11187857	C>T	E2014K	exon_44	MTOR	ENST00000361445	Bladder	Everolimus		Case report
chr1	11174420	C>T	E2419K	exon_53	MTOR	ENST00000361445	Bladder	Everolimus		Case report
chr1	11227567	T>C	N1421D	exon_29	MTOR	ENST00000361445	Bladder	Everolimus		Case report
					KIT		Gastrointestinal stromal	Imatinib		Pre-clinical
chr1	11188177	T>A	I1973F	exon_43	MTOR	ENST00000361445	Angiosarcoma;Renal	Everolimus		Case report
chr1	11193189	T>C	K1771R	exon_38	MTOR	ENST00000361445	Stomach;Anaplastic oligodendroglioma	Everolimus		Case report
chr1	11227567	T>C	N1421D	exon_29	MTOR	ENST00000361445	Stomach	Everolimus		Case report
chr1	11182179	G>T	Q2223K	exon_48	MTOR	ENST00000361445	Renal	Everolimus		Case report
chr1	11217299	A>G	L1460P	exon_30	MTOR	ENST00000361445	Any cancer type	Sirolimus		Pre-clinical
chr1	11184573	G>T	S2215Y	exon_47	MTOR	ENST00000361445	Any cancer type	Sirolimus		Pre-clinical
chr1	11169361	C>G	R2505P	exon_56	MTOR	ENST00000361445	Any cancer type	Sirolimus		Pre-clinical
					KRAS		Ovary	Decitabine;BCL2 inhibitor		Pre-clinical
					MYD88		WaldenstrÃ¶m macroglobulinemia	Ibrutinib		FDA guidelines
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Glioma;Leukemia	[]		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Glioma;Malignant peripheral nerve sheat tumor;Leukemia	[]		Pre-clinical
					NF1		Cutaneous melanoma	[]		Pre-clinical
					NF1		Cutaneous melanoma	[]		Early trials
					PDGFRA		Gastrointestinal stromal	Imatinib		Late trials
chr4	55152093	A>T	D842V	exon_18	PDGFRA	ENST00000257290	Gastrointestinal stromal	Imatinib		Late trials,Pre-clinical
					NF1		Glioma	Bevacizumab		Case report
chr4	55144547	C>T	T674I	exon_15	PDGFRA	ENST00000257290	Hyper eosinophilic advanced snydrome	Imatinib		Case report
chr17	37880213	A>G	K753E	exon_19	ERBB2	ENST00000269571	Breast adenocarcinoma	Lapatinib		Pre-clinical
chr1	156846342	G>A	G595R	exon_14	NTRK1	ENST00000524377	Any cancer type	Larotrectinib		Pre-clinical
chr15	88476265	C>T	G623R	exon_15	NTRK3	ENST00000360948	Any cancer type	Larotrectinib		Pre-clinical
					CRBN		Myeloma	Lenalidomide		Case report
chr3	3215822	G>A	Q100*	exon_3	CRBN	ENST00000231948	Myeloma	Lenalidomide		Case report
chr3	3195747	C>T	R283K	exon_8	CRBN	ENST00000231948	Myeloma	Lenalidomide		Case report
					NF1		Head an neck;Salivary glands	Everolimus		Case report
					NF1		Neurofibroma	Everolimus	Approved	Late trials
chr17	29652933	A>C	D1644A	exon_37	NF1	ENST00000358273	Head an neck	Everolimus		Case report
					LRP1B		Ovary	Liposomal Doxorubicin		Early trials
					NF1		Hepatic carcinoma	Everolimus;Pazopanib		Case report
					NF1		Plexiform neurofibroma	Imatinib		Early trials
					NF1		Plexiform neurofibroma;Malignant peripheral nerve sheat tumor	Nilotinib		Pre-clinical
					NF1		Plexiform neurofibroma	PLX3397		Pre-clinical
					NF1		Plexiform neurofibroma	Selumetinib		Early trials
					NF1		Plexiform neurofibroma	Sirolimus		Early trials
					NF1		Glioma	Sirolimus;Erlotinib		Case report
					NF1		Malignant peripheral nerve sheat tumor	Sorafenib;Sirolimus		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	Tamoxifen		Pre-clinical
chr17	37881064	C>T	T798I	exon_20	ERBB2	ENST00000269571	Breast adenocarcinoma	Neratinib		Case report
chr9	133738363	G>A	E255K	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	European LeukemiaNet guidelines
chr9	133738364	A>T	E255V	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	European LeukemiaNet guidelines
chr9	133738357	T>C	Y253H	exon_4	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	European LeukemiaNet guidelines
chr9	133748414	T>G	F359V	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	European LeukemiaNet guidelines
chr9	133748415	T>G	F359C	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	European LeukemiaNet guidelines
chr9	133748414	T>A	F359I	exon_6	ABL1	ENST00000318560	Chronic myeloid leukemia	Nilotinib	Approved	European LeukemiaNet guidelines
					NF1		Glioma	Trametinib		Case report
					NF1		Cutaneous melanoma	Trametinib		Pre-clinical
chr7	55249091	T>A	C797S	exon_20	EGFR	ENST00000275493	Lung	Osimertinib		Early trials
					EGFR		Lung	Osimertinib		Early trials
					NF1		Glioma	Vinblastine		Early trials
					NF1		Glioma	Vinblastine;Nilotinib		Case report
					EGFR		Lung	Osimertinib		Early trials
					NF2		Mesothelioma	[]		Early trials
					NF2		Mesothelioma;Ovary	[]		Pre-clinical
					NF2		Meningioma	[]		Pre-clinical
					NF2		Thyroid	[]		Pre-clinical
					NF2		Meningioma	[]		Pre-clinical
					NF2		Schwannoma;Meningioma	[]		Pre-clinical
					NF2		Schwannoma	[]		Pre-clinical
					NF2		Schwannoma	AR42		Pre-clinical
					NF2		Meningioma	AR42		Early trials
					NF2		Schwannoma	Bevacizumab		Early trials
chr7	140453136	A>T	V600E	exon_15	BRAF	ENST00000288602	Colorectal adenocarcinoma	Panitumumab		Late trials
chr7	55227926	G>A	G465R	exon_12	EGFR	ENST00000275493	Colorectal adenocarcinoma	Panitumumab		Case report
					NF2		Schwannoma	Everolimus		Early trials
					NF2		Meningioma	Everolimus;Octreotide		Pre-clinical
					NF2		Schwannoma	Imatinib		Pre-clinical
					NF2		Schwannoma;Neurofibroma	Lapatinib		Early trials
					NF2		Breast adenocarcinoma	Tensirolimus;Chemotherapy		Case report
					KRAS		Pancreas	Gemcitabine;MEK inhibitor		Early trials
					KRAS		Non-small cell lung	Selumetinib	Clinical Trials	Early trials
					NOTCH1		Acute lymphoblastic leukemia	[]		Pre-clinical
					NOTCH1		Acute lymphoblastic leukemia	[]		Pre-clinical
					NOTCH1		Acute lymphoblastic leukemia	[]		Early trials
					NOTCH1		Acute lymphoblastic leukemia	[]		Pre-clinical
					NOTCH1		Breast adenocarcinoma	[]		Pre-clinical
					NOTCH1		Mantle cell lymphoma	[]		Pre-clinical
					NOTCH1		Adenoid cystic carcinoma	[]		Case report
					NOTCH1		Any cancer type	[Ro4929097,Pf-03084014,Mk-0752]	Clinical Trials	Early trials
					NOTCH1		Any cancer type	OMP-52M51	Clinical Trials	Early trials
					NOTCH2		Breast adenocarcinoma;Acute myeloid leukemia;Acute lymphoblastic leukemia	Mk-0752	Clinical Trials	Early trials
					NOTCH2		Solid tumors	OMP-59R5	Clinical Trials	Early trials
					NPM1		Acute myeloid leukemia	[]		Pre-clinical
					NPM1		Acute myeloid leukemia	Daunorubicin	Approved	FDA guidelines
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Lung	Afatinib		NCCN/CAP guidelines
					NRAS		Cutaneous melanoma	[]	Approved	Early trials
chr1	115258748	C>A	G12C	exon_2	NRAS	ENST00000369535	Any cancer type	[]		Pre-clinical
					NRAS		Cutaneous melanoma	[]		Case report
					NRAS		Cutaneous melanoma	[]		Pre-clinical
					NRAS		Colorectal adenocarcinoma	[]		Pre-clinical
					NRAS		Acute myeloid leukemia;Lung adenocarcinoma;Acute lymphoblastic leukemia	[]		Pre-clinical
					NRAS		Cutaneous melanoma	[]		Late trials
					NRAS		Cutaneous melanoma	[]		Case report
					NRAS		Myeloma	[]		Pre-clinical
					CRBN		Myeloma	Pomalidomide		Case report
chr3	3215822	G>A	Q100*	exon_3	CRBN	ENST00000231948	Myeloma	Pomalidomide		Case report
chr3	3195747	C>T	R283K	exon_8	CRBN	ENST00000231948	Myeloma	Pomalidomide		Case report
					NRAS		Hepatic carcinoma	Sorafenib;MEK inhibitor		Early Trials,Case Report
					PALB2		Prostate adenocarcinoma	[]		Early trials
					PALB2		Pancreas	[]		Pre-clinical
					PALB2		Pancreas	Mytomycin C		Case report
					PALB2		Pancreas	Platinum Agent		Case report
					PBRM1		Any cancer type	[]		Pre-clinical
chr4	55152093	A>T	D842V	exon_18	PDGFRA	ENST00000257290	Gastrointestinal stromal	[]		Pre-clinical
					FLT3		Acute myeloid leukemia	Ponatinib		Pre-clinical
chr4	55152093	A>T	D842V	exon_18	PDGFRA	ENST00000257290	Gastrointestinal stromal	Crenolanib		Early trials
chr4	55144144	T>C	V658A	exon_14	PDGFRA	ENST00000257290	Cutaneous melanoma	Crenolanib		Pre-clinical
chr4	55141083	C>T	P577S	exon_12	PDGFRA	ENST00000257290	Cutaneous melanoma	Crenolanib		Pre-clinical
chr4	55152090	G>A	R841K	exon_18	PDGFRA	ENST00000257290	Cutaneous melanoma	Crenolanib		Pre-clinical
chr4	55152101	C>T	H845Y	exon_18	PDGFRA	ENST00000257290	Cutaneous melanoma	Crenolanib		Pre-clinical
chr4	55152126	G>A	G853D	exon_18	PDGFRA	ENST00000257290	Cutaneous melanoma	Crenolanib		Pre-clinical
					PDGFRA		Gastrointestinal stromal	Dasatinib		Pre-clinical
chr4	55152093	A>T	D842V	exon_18	PDGFRA	ENST00000257290	Gastrointestinal stromal	Dasatinib		Pre-clinical
					PDGFRA		Gastrointestinal stromal	Imatinib	Approved	NCCN guidelines
chr10	43613899	T>A	I788N	exon_13	RET	ENST00000355710	Lung adenocarcinoma	Ponatinib		Pre-clinical
					PDGFRA		Gastrointestinal stromal	Imatinib	Approved	NCCN guidelines
					FLT3		Acute myeloid leukemia	Quizartinib		Pre-clinical
chr4	55141083	C>T	P577S	exon_12	PDGFRA	ENST00000257290	Cutaneous melanoma	Imatinib		Pre-clinical
chr4	55152090	G>A	R841K	exon_18	PDGFRA	ENST00000257290	Cutaneous melanoma	Imatinib		Pre-clinical
chr4	55152101	C>T	H845Y	exon_18	PDGFRA	ENST00000257290	Cutaneous melanoma	Imatinib		Pre-clinical
chr4	55152126	G>A	G853D	exon_18	PDGFRA	ENST00000257290	Cutaneous melanoma	Imatinib		Pre-clinical
chr7	55249071	C>T	T790M	exon_20	EGFR	ENST00000275493	Lung	Erlotinib		NCCN/CAP guidelines
					PDGFRA		Gastrointestinal stromal	Regorafenib	Approved	NCCN guidelines
					PDGFRA		Gastrointestinal stromal	Sorafenib		Early trials
					PDGFRA		Gastrointestinal stromal	Sunitinib		Late trials
					PDGFRA		Gastrointestinal stromal	Sunitinib	Approved	NCCN guidelines
chr7	55249094	C>A	L798I	exon_20	EGFR	ENST00000275493	Lung adenocarcinoma	Rociletinib		Case report
					PIK3CA		Breast adenocarcinoma	[]		Early trials
					PIK3CA		Lung;Colorectal adenocarcinoma	[]		Pre-clinical
					PIK3CA		Bladder;Head an neck;Lung	[]		Case report
					PIK3CA		Breast adenocarcinoma;Ovary;Cervix squamous cell;Endometrium	[]		Early trials
					PIK3CA		Head an neck squamous	[]		Case report
					PIK3CA		Glioma;Thyroid carcinoma	[]		Pre-clinical
					KRAS		Hepatic carcinoma	Sorafenib;MEK inhibitor		Early Trials,Case Report
					PIK3CA		Breast adenocarcinoma	[]		Early trials
					PIK3CA		Stomach	[]		Case report
					PIK3CB		Head an neck squamous	[]		Pre-clinical
chr3	138374245	C>A	D1067Y	exon_23	PIK3CB	ENST00000477593	Breast adenocarcinoma	[]		Pre-clinical
					PIK3CB		Head an neck squamous	[]		Pre-clinical
chr3	138374245	C>A	D1067Y	exon_23	PIK3CB	ENST00000477593	Breast adenocarcinoma	[]		Pre-clinical
					PIK3CB		Head an neck squamous	[]		Pre-clinical
					PIK3R1		Glioma	[]		Pre-clinical
					PIK3R1		Endometrium	[]		Case report
chr19	18271909	C>T	A171V	exon_5	PIK3R2	ENST00000222254	Endometrium	[]		Pre-clinical
chr19	18278061	A>G	N561D	exon_13	PIK3R2	ENST00000222254	Endometrium	[]		Pre-clinical
					POLE		Glioma;Endometrium	[]		Case report
					POLE		Colorectal adenocarcinoma	[]		Case report
					PTCH1		Medulloblastoma	[]	Approved	Pre-clinical
					PTCH1		Medulloblastoma	Foretinib		Pre-clinical
					PTCH1		Basal cell carcinoma;Medulloblastoma	Vismodegib	Approved	FDA guidelines
					PTEN		Pancreas	[]		Case report
					PTEN		Breast adenocarcinoma	[]		Pre-clinical
					PTEN		Endometrium	[]		Case report
					PTEN		Cutaneous melanoma	[]		Early trials
					PTEN		Prostate adenocarcinoma	[]		Pre-clinical
					PTEN		Ovary	[]		Pre-clinical
					PTEN		Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium	[]		Pre-clinical
					PTEN		Prostate adenocarcinoma	[]		Case report
					KIT		Gastrointestinal stromal	Sunitinib		Late trials
					PTEN		Prostate adenocarcinoma	Everolimus		Early trials
					KIT		Gastrointestinal stromal	Sunitinib		Pre-clinical
					PTEN		Any cancer type	Sirolimus		Early trials
chr4	55152093	A>T	D842V	exon_18	PDGFRA	ENST00000257290	Gastrointestinal stromal	Sunitinib		Late trials,Pre-clinical
					ESR1		Breast adenocarcinoma	Tamoxifen		Early trials
					NF1		Plexiform neurofibroma	Tipifarnib		Early trials
					PTPRD		Sarcoma	[]		Case report
					NF1		Osteosarcoma	Trametinib		Case report
					RAD51C		Ovary	[]		Early trials
					RAD51C		Ovary	[]		Early trials
					RB1		Retinoblastoma	[]		Pre-clinical
					RB1		Retinoblastoma	[]		Pre-clinical
					RB1		Bladder	Cisplatin	Approved	Early trials
chr10	43609950	C>G	C634W	exon_11	RET	ENST00000355710	Thyroid	[]		Pre-clinical
chr10	43617416	T>C	M918T	exon_16	RET	ENST00000355710	Thyroid	[]		Pre-clinical
chr10	43609950	C>G	C634W	exon_11	RET	ENST00000355710	Thyroid	Cabozantinib		Pre-clinical
chr10	43617416	T>C	M918T	exon_16	RET	ENST00000355710	Thyroid	Cabozantinib		Pre-clinical
chr10	43609950	C>G	C634W	exon_11	RET	ENST00000355710	Thyroid	Sunitinib		Pre-clinical
chr10	43617416	T>C	M918T	exon_16	RET	ENST00000355710	Thyroid	Sunitinib		Pre-clinical
					RET		Thyroid carcinoma	Vandetanib	Approved	FDA guidelines
					RNF43		Colorectal adenocarcinoma	[]		Case report
chr6	117638347	C>T	G2032R	exon_38	ROS1	ENST00000368508	Lung adenocarcinoma	Cabozantinib		Pre-clinical
chr6	117639399	G>T	S1986Y	exon_37	ROS1	ENST00000368508	Lung adenocarcinoma	Lorlatinib		Case report
chr6	117639399	G>A	S1986F	exon_37	ROS1	ENST00000368508	Lung adenocarcinoma	Lorlatinib		Case report
					SERPINB3		Cutaneous melanoma	[]		Early trials
					SETD2		Any cancer type	[]		Pre-clinical
chr2	198266834	T>C	K700E	exon_15	SF3B1	ENST00000335508	Any cancer type	[]		Pre-clinical
chr2	198267359	C>G	K666N	exon_14	SF3B1	ENST00000335508	Any cancer type	[]		Pre-clinical
					SH2B3		Myelodisplasic proliferative syndrome	[]		Pre-clinical
					SMARCA1		Any cancer type	[]		Pre-clinical
					SMARCA4		Ovary	[]		Case report
					SMARCB1		Malignant rhabdoid tumor	[]		Case report
					SMARCB1		Malignant rhabdoid tumor	[]		Pre-clinical
					KRAS		Lung adenocarcinoma	Trametinib;Ponatinib		Pre-clinical
chr7	128851596	C>G	P641A	exon_11	SMO	ENST00000249373	Lung	Vismodegib		Case report
					SRSF2		Acute myeloid leukemia	[]		Pre-clinical
					STAG2		Glioma	[]		Pre-clinical
					BRAF		Any cancer type	Vemurafenib	Approved	Pre-clinical
					STK11		Lung adenocarcinoma	[]		Pre-clinical
					STK11		Any cancer type	[]		Pre-clinical
					STK11		Lung adenocarcinoma	[]		Pre-clinical
chr19	1220489	C>G	D194E	exon_4	STK11	ENST00000326873	Pancreas	Everolimus		Case report
					STK11		Lung adenocarcinoma	Phenformin		Pre-clinical
					BRAF		Colorectal adenocarcinoma	Vemurafenib	Approved	Early trials
chr15	66774131	G>A	E203K	exon_6	MAP2K1	ENST00000307102	Cutaneous melanoma	Vemurafenib		Case report
chr15	66727451	A>C	Q56P	exon_2	MAP2K1	ENST00000307102	Cutaneous melanoma	Vemurafenib		Case report
chr15	66727453	A>G	K57E	exon_2	MAP2K1	ENST00000307102	Cutaneous melanoma	Vemurafenib		Case report
					SUZ12		Any cancer type	[]		Pre-clinical
					TERT		Glioblastoma multiforme	Eribulin		Pre-clinical
					TP53		Acute myeloid leukemia	[]		Early trials
chr17	7577538	C>T	R248Q	exon_7	TP53	ENST00000269305	Any cancer type	[]		Pre-clinical
chr17	7578406	C>T	R175H	exon_5	TP53	ENST00000269305	Any cancer type	[]		Pre-clinical
chr17	7577538	C>T	R248Q	exon_7	TP53	ENST00000269305	Any cancer type	[]		Pre-clinical
chr17	7578406	C>T	R175H	exon_5	TP53	ENST00000269305	Any cancer type	[]		Pre-clinical
					TP53		Head an neck	[]		Pre-clinical
					TP53		B cell lymphoma	AZD6738	Clinical Trials	Early trials
					NRAS		Cutaneous melanoma	Vemurafenib		Pre-clinical
					TP53		Acute myeloid leukemia;Myelodisplasic proliferative syndrome	Decitabine		Early trials
					TP53		Bladder	Doxorubicin		Pre-clinical
					TP53		Bladder	Gemcitabine		Pre-clinical
					TP53		Bladder	Mitomycin C		Pre-clinical
					TP53		Ovary	[]	Clinical Trials	Early trials
					TP53		Thymic	Pramlintide		Pre-clinical
					TPMT		Any cancer type	Cisplatin	Approved	FDA guidelines
chr6	18143955	C>G	A80P	exon_4	TPMT	ENST00000309983	Any cancer type	Cisplatin	Approved	FDA guidelines
chr6	18130918	T>C	Y240C	exon_9	TPMT	ENST00000309983	Any cancer type	Cisplatin	Approved	FDA guidelines
chr6	18139228	C>T	A154T	exon_6	TPMT	ENST00000309983	Any cancer type	Cisplatin	Approved	FDA guidelines
chr6	18134115	G>C	A167G	exon_7	TPMT	ENST00000309983	Any cancer type	Cisplatin	Approved	FDA guidelines
					TPMT		Any cancer type	Mercaptopurine	Approved	FDA guidelines
chr6	18143955	C>G	A80P	exon_4	TPMT	ENST00000309983	Any cancer type	Mercaptopurine	Approved	FDA guidelines
chr6	18130918	T>C	Y240C	exon_9	TPMT	ENST00000309983	Any cancer type	Mercaptopurine	Approved	FDA guidelines
chr6	18139228	C>T	A154T	exon_6	TPMT	ENST00000309983	Any cancer type	Mercaptopurine	Approved	FDA guidelines
chr6	18134115	G>C	A167G	exon_7	TPMT	ENST00000309983	Any cancer type	Mercaptopurine	Approved	FDA guidelines
					TPMT		Any cancer type	Thioguanine	Approved	FDA guidelines
chr6	18143955	C>G	A80P	exon_4	TPMT	ENST00000309983	Any cancer type	Thioguanine	Approved	FDA guidelines
chr6	18130918	T>C	Y240C	exon_9	TPMT	ENST00000309983	Any cancer type	Thioguanine	Approved	FDA guidelines
chr6	18139228	C>T	A154T	exon_6	TPMT	ENST00000309983	Any cancer type	Thioguanine	Approved	FDA guidelines
chr6	18134115	G>C	A167G	exon_7	TPMT	ENST00000309983	Any cancer type	Thioguanine	Approved	FDA guidelines
chr15	88476265	C>T	G623R	exon_15	NTRK3	ENST00000360948	Any cancer type	[]		Case report
					FLT3		Acute myeloid leukemia	Venetoclax		Early trials
					TSC1		Renal angiomyolipoma	[]		Early trials
					TSC1		Bladder	Everolimus	Approved	Early trials
					TSC1		Renal	Everolimus		Case report
					TSC1		Giant cell astrocytoma	Everolimus	Approved	FDA guidelines
					TSC1		Sarcoma;Stomach	Everolimus	Approved	Case report
					TSC1		Renal angiomyolipoma	Everolimus	Approved	FDA guidelines
					TSC2		Renal angiomyolipoma	[]		Early trials
					TSC2		Lymphangioleiomyomatosis	[]		Pre-clinical
					TSC2		Bladder	Everolimus	Approved	Early trials
					TSC2		Renal angiomyolipoma;Giant cell astrocytoma	Everolimus	Approved	FDA guidelines
chr16	2130300	C>T	Q1178*	exon_30	TSC2	ENST00000219476	Thyroid carcinoma	Everolimus	Approved	Case report
chr16	2100458	G>A	E66K	exon_3	TSC2	ENST00000219476	Endometrium	Tensirolimus		Case report
chr7	128849189	G>C	D473H	exon_8	SMO	ENST00000249373	Medulloblastoma	Vismodegib		Case report
					U2AF1		Any cancer type	[]		Pre-clinical
chr2	234669144	G>A	G71R	exon_1	UGT1A1	ENST00000305208	Any cancer type	Irinotecan	Approved	FDA guidelines
chr2	234669619	C>A	P229Q	exon_1	UGT1A1	ENST00000305208	Any cancer type	Irinotecan	Approved	FDA guidelines
chr2	234669144	G>A	G71R	exon_1	UGT1A1	ENST00000305208	Any cancer type	Nilotinib	Approved	FDA guidelines
chr2	234669619	C>A	P229Q	exon_1	UGT1A1	ENST00000305208	Any cancer type	Nilotinib	Approved	FDA guidelines
					VHL		Renal	[Sorafenib,Sunitinib,Bevacizumab,Axitinib]	Approved	Pre-clinical
chr7	128849189	G>C	D473H	exon_8	SMO	ENST00000249373	Basal cell carcinoma	Vismodegib		Case report
chr7	128849190	A>G	D473G	exon_8	SMO	ENST00000249373	Basal cell carcinoma	Vismodegib		Case report
chr7	128850341	G>T	W535L	exon_9	SMO	ENST00000249373	Basal cell carcinoma	Vismodegib		Case report
chr7	128846398	C>T	L412F	exon_6	SMO	ENST00000249373	Basal cell carcinoma	Vismodegib		Case report
chr7	128845546	G>T	W281C	exon_4	SMO	ENST00000249373	Basal cell carcinoma	Vismodegib		Case report
chr7	128849201	C>G	Q477E	exon_8	SMO	ENST00000249373	Basal cell carcinoma	Vismodegib		Case report
chr7	128850226	G>T	G497W	exon_9	SMO	ENST00000249373	Basal cell carcinoma	Vismodegib		Case report
					ZNRF3		Colorectal adenocarcinoma	[]		Pre-clinical
					ABL1		Chronic myeloid leukemia	Bosutinib	Approved	FDA guidelines
					ABL1		Chronic myeloid leukemia;Acute lymphoblastic leukemia	Dasatinib	Approved	FDA guidelines
					ABL1		Acute lymphoblastic leukemia	Dasatinib;Venetoclax		Pre-clinical
					ABL1		Chronic myeloid leukemia;Acute lymphoblastic leukemia	Imatinib	Approved	FDA guidelines
					ABL1		Chronic myeloid leukemia	Nilotinib	Approved	FDA guidelines
					ABL1		Chronic myeloid leukemia;Acute lymphoblastic leukemia	Ponatinib	Approved	FDA guidelines
					AKT2		Any cancer type	MK2206	Clinical Trials	Pre-clinical
					AKT3		Breast adenocarcinoma	[AZD5363,GSK2141795]	Clinical Trials;Clinical Trials	Pre-clinical
					ALK		Lung adenocarcinoma	[]		Pre-clinical
					ALK		Lung adenocarcinoma	[]		Pre-clinical
					ALK		Lung adenocarcinoma	[]		Pre-clinical
					ALK		Colorectal adenocarcinoma	[]		Case report
					ALK		Lung adenocarcinoma	[]		Early trials
					ALK		Lung adenocarcinoma	[]		Early trials
					ALK		Lung adenocarcinoma	Alectinib		FDA guidelines
					ALK		Non-small cell lung	Alectinib	Clinical_Trials	FDA guidelines
					CCND1		Medulloblastoma	[]		Pre-clinical
					ALK		Lung adenocarcinoma	Brigatinib		Case report
					ALK		Non-small cell lung;Lung adenocarcinoma	Ceritinib	Approved	FDA guidelines
					ALK		Colorectal adenocarcinoma;Inflammatory myofibroblastic	Ceritinib		Case report
					ALK		Hematologic malignancies	Ceritinib	Clinical Trials	Early trials
					ALK		Lymphoma;Glioblastoma	Crizotinib		Early trials
					ALK		Non-small cell lung;Lung adenocarcinoma	Crizotinib	Approved	FDA guidelines
					ALK		Inflammatory myofibroblastic;Thyroid carcinoma	Crizotinib		Case report
					EGFR		Glioma	[]		Early trials
					EGFR		Glioma	[]		Early trials
					ALK		Colorectal adenocarcinoma	Entrictinib		Case report
					ALK		Non-small cell lung	Lorlatinib		Early trials
					ALK		Non-small cell lung	Brigatinib		FDA guidelines
					EGFR		Glioma	[]		Early trials
					AR		Prostate adenocarcinoma	[]		Pre-clinical
					AR		Breast adenocarcinoma	[Bicalutamide,Enzalutamide,Orterone,4OHtestosterone]	Clinical Trials	Early trials
					ERBB2		Lung adenocarcinoma	[]		Pre-clinical
					ERBB2		Colorectal adenocarcinoma	[]		Early trials
					ERBB3		Colorectal adenocarcinoma	[]		Early trials
					ESR1		Breast adenocarcinoma	[]		Pre-clinical
					AR		Prostate adenocarcinoma	Enzalutamide	Approved	Early trials
					AR;AR		Prostate adenocarcinoma	Enzalutamide		Pre-clinical
					FBXW7		Any cancer type	[]		Pre-clinical
					FGFR2;FGFR2		Cholangiocarcinoma	[]		Early trials
					AREG		Colorectal adenocarcinoma	[]		Early trials
					GLI2		Medulloblastoma	[]		Pre-clinical
					ATM		Colorectal adenocarcinoma	[]		Case report
					ATM		Lymphoma	[]		Pre-clinical
					ATM		Stomach	[]		Early trials
					ATM		B cell lymphoma	AZD6738	Clinical Trials	Early trials
					ATM		Bladder	Cisplatin	Approved	Early trials
					ATR		Ovary;Any cancer type	Olaparib	Approved	Pre-clinical
					AURKA		Prostate adenocarcinoma;Any cancer type	[]		Pre-clinical
					IGF2		Colorectal adenocarcinoma	[]		Early trials
					BAP1		Mesothelioma	[]		Pre-clinical
					BAP1		Cutaneous melanoma	[]		Pre-clinical
					BAP1		Renal;Any cancer type	[]		Pre-clinical
					BCL2		Multiple myeloma	Venetoclax;Bortezomib		Early trials
					BCL2		Lymphoma	[]		Pre-clinical
					BCL6		Lymphoma	Onalespib		Early trials
					BRAF		Lung adenocarcinoma	[]		Case report
					BRAF		Lung adenocarcinoma;Cutaneous melanoma;Prostate adenocarcinoma	[Trametinib]		Pre-clinical
					BRAF		Ovary	Selumetinib		Case report
					BRAF		Cutaneous melanoma;Lung adenocarcinoma;Prostate adenocarcinoma	Sorafenib		Pre-clinical
					KRAS		Colorectal adenocarcinoma	[]		Case report
					BRAF;EGFR		Lung adenocarcinoma	[]		Pre-clinical
					BRCA1		Ovary	[]		Pre-clinical
					BRCA2		Ovary	[Olaparib]		Pre-clinical
					KRAS		Colorectal adenocarcinoma	[]		Case report
					C15orf55		NUT midline carcinoma	[]		Case report
					CA9		Renal	Sunitinib	Approved	Pre-clinical
					CCND1		Cutaneous melanoma	[]		Case report
					CCND1		Any cancer type	[]		Pre-clinical
					CCND2		Any cancer type	[]		Pre-clinical
					CCND2		Lung	Palbociclib	Approved	Early trials
					CCND3		Any cancer type	[]		Pre-clinical
					CCNE1		Any cancer type	[]		Pre-clinical
					CD274		Basal cell carcinoma	[]		Case report
					CD274		Any cancer type	[]		Pre-clinical
					CD274		Cutaneous melanoma;Renal;Any cancer type	Atezolizumab	Clinical Trials	Early trials
					CD274		Renal	Nivolumab	Clinical Trials	Early trials
					CD274		Bladder	Pembrolizumab	Clinical Trials	Early trials
					CD69		Chronic lymphocytic leukemia	Bendamustine	Approved	Pre-clinical
					CDK12		Ovary	[]		Pre-clinical
					CDK4		Liposarcoma;Lymphoma;Any cancer type	LEE011	Clinical Trials	Early trials
					CDK4;RB1		Liposarcoma	[]		Early trials
					CDK6		Any cancer type	[]		Pre-clinical
					CDK6		Liposarcoma;Lymphoma;Any cancer type	LEE011	Clinical Trials	Early trials
					CDKN1A		Any cancer type	[]		Pre-clinical
					CDKN1B		Any cancer type	[]		Pre-clinical
					CDKN2A		Cutaneous melanoma	[]		Case report
					CDKN2A		Glioma;Any cancer type	[]		Pre-clinical
					CDKN2A		Any cancer type	Ilorasertib	Clinical Trials	Early trials
					CDKN2B		Glioma;Any cancer type	[]		Pre-clinical
					CDKN2C		Glioma;Any cancer type	[]		Pre-clinical
					CHEK2		Prostate adenocarcinoma	Olaparib		Early trials
					CRLF2		Acute lymphoblastic leukemia	[]		Pre-clinical
					CRLF2		Acute lymphoblastic leukemia	[]		Pre-clinical
					CYP17A1		Prostate adenocarcinoma	Abiraterone	Approved	Early trials
					CYP17A1		Prostate adenocarcinoma	Enzalutamide	Approved	Early trials
					DPYD		Any cancer type	Capecitabine	Approved	FDA guidelines
					DPYD		Any cancer type	Flourouracil	Approved	FDA guidelines
					DPYD		Any cancer type	Tegafur	Approved	CPIC guidelines
					MCL1		Any cancer type	[]		Pre-clinical
					MET		Non-small cell lung;Colorectal adenocarcinoma	[]		Early trials
					MET		Colorectal adenocarcinoma	[]		Early trials
					MET;EGFR		Lung adenocarcinoma	[]		Early trials
					MITF		Cutaneous melanoma	[]		Case report
					MITF		Cutaneous melanoma	[]		Case report
					MYCN		Medulloblastoma	[]		Pre-clinical
					EGFR		Head an neck squamous	[]		Case report
					EGFR		Colorectal adenocarcinoma	[]		Late trials
					NF1		Neuroblastoma	[]		Pre-clinical
					EGFR		Colorectal adenocarcinoma	Cetuximab	Approved	FDA guidelines
					EGFR		Non-small cell lung	Erlotinib	Approved	Case report
					EGFR		Lung	Erlotinib		Case report
					PDGFRA		Glioma	[]		Pre-clinical
					PIK3CA		Breast adenocarcinoma	[]		Pre-clinical
					EGFR		Endometrium	Gefitinib	Approved	Late trials
					PTEN		Colorectal adenocarcinoma	[]		Late trials
					PTEN		Endometrium	[]		Early trials
					PTEN;BRAF		Cutaneous melanoma	[]		Early trials
					PTEN;BRAF		Cutaneous melanoma	[]		Early trials
					EPHA2		Any cancer type	Dasatinib		Pre-clinical
					EPHA2		Any cancer type	Dasatinib		Pre-clinical
					EPHA3		Any cancer type	[]		Pre-clinical
					EPHA3		Any cancer type	[]		Pre-clinical
					PTEN;BRAF		Cutaneous melanoma	[]		Pre-clinical
					PTEN;BRAF		Cutaneous melanoma	[]		Pre-clinical
					ERBB2		Breast adenocarcinoma	[]		Pre-clinical
					ERBB2		Breast adenocarcinoma	Ado-Trastuzumab Emtansine		FDA guidelines
					ERBB2		Breast adenocarcinoma	Ado-Trastuzumab Emtansine	Approved	FDA guidelines
					ERBB2		Stomach	Afatinib		Case report
					ERBB2		Breast adenocarcinoma	Afatinib		Late trials
					ERBB2		Bladder	Afatinib		Case report
					ERBB2		Breast adenocarcinoma	Lapatinib		FDA guidelines
					ERBB2		Billiary tract	Lapatinib		Early trials
					RAC1;BRAF		Cutaneous melanoma	[]		Case report
					ERBB2		Breast adenocarcinoma	Lapatinib	Approved	FDA guidelines
					ERBB2		Stomach	Lapatinib;Chemotherapy		Early trials
					ERBB2		Solid tumors	MK2206;Trastuzumab		Early trials
					ERBB2		Breast adenocarcinoma	Neratinib		Late trials
					RAC1;BRAF		Cutaneous melanoma	[]		Case report
					RAF1;BRAF		Cutaneous melanoma	[]		Pre-clinical
					ERBB2		Stomach	Pertuzumab		Early trials
					ERBB2		Breast adenocarcinoma	Pertuzumab		FDA guidelines
					ERBB2		Billiary tract	Pertuzumab		Early trials
					ERBB2		Breast adenocarcinoma	Pertuzumab	Approved	FDA guidelines
					ERBB2		Stomach;Gastroesophageal junction adenocarcinoma	Trastuzumab		FDA guidelines
					ERBB2		Breast adenocarcinoma	Trastuzumab		FDA guidelines
					ERBB2		Billiary tract	Trastuzumab		Early trials
					ERBB2		Head an neck	Trastuzumab		Case report
					ERBB2		Ovary	Trastuzumab		Early trials
					ERBB2		Breast adenocarcinoma	Trastuzumab	Approved	FDA guidelines
					ERBB2		Stomach;Gastroesophageal junction adenocarcinoma	Trastuzumab	Approved	FDA guidelines
					ERBB2		Colorectal adenocarcinoma	Ado-Trastuzumab Emtansine		Case report
					ERBB2		Breast adenocarcinoma	Trastuzumab;Everolimus;Chemotherapy		Early trials
					ERBB2		Breast adenocarcinoma	Trastuzumab;HSP90 inhibitor		Early trials
					ERBB2		Colorectal adenocarcinoma	Trastuzumab;Lapatinib		Late trials
					ERBB2		Endometrium	Trastuzumab;Lapatinib		Pre-clinical
					ERBB2;ESR1		Breast adenocarcinoma	[Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist]	Approved	FDA guidelines
					ERBB2;ESR1		Breast adenocarcinoma	Abemaciclib		Early trials
					ERBB2;ESR1		Breast adenocarcinoma	Everolimus	Approved	FDA guidelines
					ERBB2;ESR1		Breast adenocarcinoma	Palbociclib	Approved	FDA guidelines
					STK11;KRAS		Lung adenocarcinoma	[]		Early trials
					STK11;KRAS		Lung adenocarcinoma	[]		Early trials
					ERBB4		Lung adenocarcinoma	Lapatinib;Afatinib		Pre-clinical
					ERCC1		Lung	[]		Pre-clinical
					ERCC1		Lung	Cisplatin		Pre-clinical
					EREG		Colorectal adenocarcinoma	[]		Early trials
					ZBTB16		Prostate adenocarcinoma	[]		Pre-clinical
					FANCA		Prostate adenocarcinoma	Olaparib		Case report
					FANCC		Bladder	Cisplatin	Approved	Early trials
					FBXW7		Colorectal adenocarcinoma	Sirolimus	Approved	Pre-clinical
					FGF3		Breast adenocarcinoma	Dovitinib		Early trials
					FGF3		Breast adenocarcinoma	Lucitanib	Clinical Trials	Early trials
					FGF4		Breast adenocarcinoma	Dovitinib		Early trials
					FGF4		Breast adenocarcinoma	Lucitanib	Clinical Trials	Early trials
					FGFR1		Lung squamous cell	[]		Case report
					FGFR1		Endometrium	[]		Case report
					FGFR1		Lung squamous cell	[]		Early trials
					FGFR1		Head an neck	[]		Pre-clinical
					FGFR1		Breast adenocarcinoma	[Lucitanib]		Early trials
					AR		Prostate adenocarcinoma	Abiraterone	Approved	Early trials
					FGFR2		Billiary tract	[]		Early trials
					FGFR2		Stomach	[]		Early trials
					FGFR2		Breast adenocarcinoma	[]		Case report
					EGFR		Colorectal adenocarcinoma	Panitumumab	Approved	FDA guidelines
					FGFR2		Colorectal adenocarcinoma	[]		Early trials
					FGFR3		Glioma	[]		Early trials
					FGFR3		Bladder	[]		Case report
					FGFR3		Non-small cell lung			Pre-clinical
					FLCN		Thyroid	Everolimus		Case report
					FLT1		Renal	Sunitinib	Approved	Pre-clinical
					FLT1		Renal	Sunitinib	Approved	Pre-clinical
					PTEN		Breast adenocarcinoma	BYL719	Clinical Trials	Case report
					NF1		Plexiform neurofibroma	Cediranib		Early trials
					FOXA1		Colorectal adenocarcinoma	[]		Pre-clinical
					FRS2		Liposarcoma	[]		Pre-clinical
					G6PD		Any cancer type	Dabrafenib	Approved	FDA guidelines
					G6PD;G6PD		Any cancer type	Dabrafenib	Approved	FDA guidelines
					HDAC2		Prostate adenocarcinoma	Olaparib		Case report
					HGF		Urinary tract carcinoma	Cabozantinib	Approved	Pre-clinical
					HIF1A		Renal	Sunitinib	Approved	Pre-clinical
					IL7R;SH2B3		Acute lymphoblastic leukemia	[]		Pre-clinical
					IL7R;SH2B3		Acute lymphoblastic leukemia	[]		Pre-clinical
					IL7R;SH2B3		Acute lymphoblastic leukemia	Ruxolitinib		Pre-clinical
					IL7R;SH2B3		Acute lymphoblastic leukemia	Ruxolitinib		Pre-clinical
					INPP4B		Breast adenocarcinoma	[]		Pre-clinical
					JAK2		Breast adenocarcinoma	[]		Pre-clinical
					JAK2		Acute lymphoblastic leukemia	Ruxolitinib		Pre-clinical
					PTEN		Colorectal adenocarcinoma	Cetuximab	Approved	Case report
					ERCC1		Bladder	Cisplatin	Approved	Pre-clinical
					MDM2		Male germ cell tumor	Cisplatin		Early trials
					ALK		Non-small cell lung	Crizotinib	Approved	Clinical trials
					ALK		Lung adenocarcinoma	Crizotinib		Case report
					NF1		Lung	Dasatinib		Pre-clinical
					EGFR		Lung	Erlotinib	Approved	Early trials
					IGF1R		Lung adenocarcinoma	Erlotinib		Pre-clinical
					NF1		Lung	Erlotinib		Pre-clinical
					NF2		Schwannoma	Erlotinib		Early trials
					NF2;EGFR		Lung	Erlotinib;Cetuximab		Case report
					NF2;EGFR		Lung	Erlotinib;Cetuximab		Case report
					NF1		Malignant peripheral nerve sheat tumor	Everolimus		Early trials
					NF1		Malignant peripheral nerve sheat tumor	Everolimus;Bevacizumab		Early trials
					MAP2K1;BRAF		Cutaneous melanoma	[]		Case report
					NF1		Glioma	Everolimus;Erlotinib		Case report
					MDM2		Liposarcoma	[]		Early trials
					MDM4		Sarcoma	[]		Pre-clinical
					EGFR		Head an neck	Gefitinib	Approved	Early trials
					MET		Colorectal adenocarcinoma	[]		Pre-clinical
					MET		Hepatic carcinoma	[]		Case report
					MET		Stomach	[]		Pre-clinical
					MET		Renal	[]		Early trials
					MET		Colorectal adenocarcinoma	Cabozantinib;Panitumumab	Clinical Trials	Case report
					MET		Glioma	Crizotinib		Case report
					MET		Non-small cell lung	Crizotinib	Clinical Trials	Early trials
					MET		Lung adenocarcinoma;Stomach	Crizotinib		Early trials
					MET		Glioma	Crizotinib		Case report
					MET;BRAF		Colorectal adenocarcinoma	Crizotinib;Vemurafenib		Case report
					MET;ERBB2		Stomach	Crizotinib;Trastuzumab		Case report
					MET;ERBB2		Stomach	Crizotinib;Trastuzumab		Case report
					KIT		Cutaneous melanoma	Imatinib		Early trials
					MKI67		Renal	Sunitinib	Approved	Pre-clinical
					MLL		Acute myeloid leukemia	[]		Pre-clinical
					MLL		Acute myeloid leukemia	Belinostat	Approved	Early trials
					MLL		Acute myeloid leukemia	Daunorubicin	Approved	FDA guidelines
					MLL		Acute myeloid leukemia;Acute lymphoblastic leukemia;Myelodisplasic syndrome	EPZ-5676	Clinical Trials	Early trials
					MYC		Myeloma;Neuroblastoma	[]		Pre-clinical
					MYC		Neuroblastoma	[]		Pre-clinical
					MYC		Neuroblastoma	[]		Pre-clinical
					MYC		Prostate adenocarcinoma	[]		Pre-clinical
					MYC		Colorectal adenocarcinoma	Temozolomide		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Glioma;Leukemia	[]		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	[]		Pre-clinical
					NF1		Glioma;Malignant peripheral nerve sheat tumor;Leukemia	[]		Pre-clinical
					NF1		Cutaneous melanoma	[]		Pre-clinical
					NF1		Cutaneous melanoma	[]		Early trials
					NF1		Glioma	Bevacizumab		Case report
					MET;ERBB2		Stomach	Lapatinib		Pre-clinical
					CRBN		Myeloma	Lenalidomide		Case report
					NF1		Head an neck;Salivary glands	Everolimus		Case report
					LRP1B		Ovary	Liposomal Doxorubicin		Early trials
					STK11;KRAS		Lung adenocarcinoma	MEK inhibitor;Docetaxel		Pre-clinical
					STK11;KRAS		Lung adenocarcinoma	MEK inhibitor;Docetaxel		Pre-clinical
					NF1		Plexiform neurofibroma	Imatinib		Early trials
					NF1		Plexiform neurofibroma;Malignant peripheral nerve sheat tumor	Nilotinib		Pre-clinical
					NF1		Plexiform neurofibroma	PLX3397		Pre-clinical
					NF1		Plexiform neurofibroma	Selumetinib		Early trials
					NF1		Plexiform neurofibroma	Sirolimus		Early trials
					NF1		Glioma	Sirolimus;Erlotinib		Case report
					NF1		Malignant peripheral nerve sheat tumor	Sorafenib;Sirolimus		Pre-clinical
					NF1		Malignant peripheral nerve sheat tumor	Tamoxifen		Pre-clinical
					NF1		Glioma	Trametinib		Case report
					NF1		Cutaneous melanoma	Trametinib		Pre-clinical
					NF1		Glioma	Vinblastine		Early trials
					NF1		Glioma	Vinblastine;Nilotinib		Case report
					ERBB2		Lung adenocarcinoma	Osimertinib	Approved	Case report
					MET		Lung adenocarcinoma	Osimertinib	Approved	Case report
					TUBB3		Bladder	Paclitaxel		Pre-clinical
					CCND1		Lung	Palbociclib		Early trials
					CDK4		Lung	Palbociclib		Early trials
					NF2		Mesothelioma	[]		Early trials
					NF2		Mesothelioma;Ovary	[]		Pre-clinical
					NF2		Meningioma	[]		Pre-clinical
					NF2		Thyroid	[]		Pre-clinical
					NF2		Meningioma	[]		Pre-clinical
					NF2		Schwannoma;Meningioma	[]		Pre-clinical
					NF2		Schwannoma	[]		Pre-clinical
					NF2		Schwannoma	AR42		Pre-clinical
					NF2		Meningioma	AR42		Early trials
					NF2		Schwannoma	Bevacizumab		Early trials
					NF2		Schwannoma	Everolimus		Early trials
					NF2		Meningioma	Everolimus;Octreotide		Pre-clinical
					NF2		Schwannoma	Imatinib		Pre-clinical
					NF2		Schwannoma;Neurofibroma	Lapatinib		Early trials
					NF2		Breast adenocarcinoma	Tensirolimus;Chemotherapy		Case report
					NOTCH1		Acute lymphoblastic leukemia	[]		Pre-clinical
					NOTCH1		Breast adenocarcinoma	[]		Pre-clinical
					NOTCH2		Breast adenocarcinoma	[]		Pre-clinical
					PTEN		Colorectal adenocarcinoma	Panitumumab		Case report
					CRBN		Myeloma	Pomalidomide		Case report
					NRG1		Lung adenocarcinoma	Afatinib		Case report
					NRG1		Lung adenocarcinoma	Lapatinib		Pre-clinical
					NTRK1		Lung adenocarcinoma	[]		Pre-clinical
					NTRK1		Any cancer type	[]		Early trials
					NTRK1		Colorectal adenocarcinoma	[Entrectinib]		Case report
					NTRK1		Lung adenocarcinoma	Crizotinib		Case report
					NTRK3		Breast adenocarcinoma	[]		Pre-clinical
					NTRK3		Breast adenocarcinoma	[]		Pre-clinical
					NTRK3		Breast adenocarcinoma	Midostaurin		Pre-clinical
					PAK1		Cutaneous melanoma	[]		Pre-clinical
					PALB2		Prostate adenocarcinoma	[]		Early trials
					PALB2		Pancreas	[]		Pre-clinical
					PALB2		Pancreas	Mytomycin C		Case report
					PALB2		Pancreas	Platinum Agent		Case report
					PBRM1		Any cancer type	[]		Pre-clinical
					PBRM1		Renal	Everolimus	Approved	Pre-clinical
					PDGFRA		Myelodisplasic syndrome;Myelodisplasic proliferative syndrome	Imatinib	Approved	FDA guidelines
					PDGFRA		Hyper eosinophilic advanced snydrome;Eosinophilic chronic leukemia	Imatinib	Approved	FDA guidelines
					PDGFRA		Renal	Sunitinib	Approved	Pre-clinical
					PDGFB		Dermatofibrosarcoma	Imatinib	Approved	FDA guidelines
					PDPK1		Breast adenocarcinoma	[]		Pre-clinical
					ERBB2		Lung adenocarcinoma	Rociletinib		Case report
					MET		Lung adenocarcinoma	Rociletinib		Case report
					NF1;BRAF		Cutaneous melanoma	Selumetinib		Case report
					PIK3CA;ERBB2		Breast adenocarcinoma	Everolimus;Trastuzumab;Chemotherapy		Late trials
					NF1;BRAF		Cutaneous melanoma	Selumetinib		Case report
					PML		Acute promyelocytic leukemia	Tretinoin	Approved	FDA guidelines
					PML		Acute myeloid leukemia	Tretinoin;Arsenic Trioxide	Approved	FDA guidelines
					PML		Acute myeloid leukemia	Volasertib	Clinical Trials	Early trials
					PRKCH;ABL1		Chronic myeloid leukemia	Trametinib;Imatinib		Pre-clinical
					PTEN		Pancreas	[]		Case report
					PTEN		Endometrium	[]		Case report
					PTEN		Cutaneous melanoma	[]		Early trials
					PTEN		Prostate adenocarcinoma	[]		Pre-clinical
					PTEN		Ovary	[]		Pre-clinical
					PTEN		Thyroid;Glioma;Lung;Ovary;Breast adenocarcinoma;Any cancer type;Endometrium	[]		Pre-clinical
					PTEN		Prostate adenocarcinoma	[]		Case report
					PTEN		Prostate adenocarcinoma	Everolimus		Early trials
					PTEN		Any cancer type	Sirolimus		Early trials
					KIT		Cutaneous melanoma	Sunitinib		Early trials
					PTEN;ERBB2		Breast adenocarcinoma	Everolimus;Trastuzumab;Chemotherapy		Late trials
					NF1		Plexiform neurofibroma	Tipifarnib		Early trials
					RAD50;ATM		Any cancer type	Irinotecan;CHK1/2 inhibitor		Case report
					RAF1		Prostate adenocarcinoma	[]	Pre-clinical	Pre-clinical
					RAF1		Prostate adenocarcinoma	Sorafenib		Pre-clinical
					RAF1		Osteosarcoma	Sorafenib		Pre-clinical
					RAF1		Prostate adenocarcinoma	U0126	Approved	Pre-clinical
					NF1		Osteosarcoma	Trametinib		Case report
					RB1		Retinoblastoma	[]		Pre-clinical
					RB1		Retinoblastoma	[]		Pre-clinical
					RB1		Bladder	Cisplatin	Approved	Early trials
					RB1		Prostate adenocarcinoma	Palbociclib	Pre-clinical	Pre-clinical
					RET		Lung adenocarcinoma	[]		Pre-clinical
					RET		Thyroid	[]		Pre-clinical
					RET		Lung adenocarcinoma	Cabozantinib		Early trials
					RET		Thyroid carcinoma	Cabozantinib		Pre-clinical
					RET		Lung adenocarcinoma	Nintedanib		Case report
					ARID1A;ANXA1		Breast adenocarcinoma	Trastuzumab	FDA approved	Early trials
					RET		Lung adenocarcinoma	Sunitinib		Early trials
					RET		Thyroid carcinoma	Sunitinib		Pre-clinical
					RET		Lung adenocarcinoma	Vandetanib		Early trials
					RET		Thyroid carcinoma	Vandetanib		Pre-clinical
					RICTOR		Lung	[]		Case report
					ROS1		Lung adenocarcinoma	[]		Pre-clinical
					ROS1		Lung adenocarcinoma	Cabozantinib		Case report
					ARID1A;ANXA1		Breast adenocarcinoma	Trastuzumab	FDA approved	Early trials
					ROS1		Inflammatory myofibroblastic	Crizotinib		Case report
					ROS1		Lung adenocarcinoma	Crizotinib		Early trials
					ROS1		Non-small cell lung	Crizotinib	Clinical trials	FDA guidelines
					ERBB2		Endometrium	Trastuzumab		Early trials
					HGF;ERBB2		Breast adenocarcinoma	Trastuzumab		Early trials
					SETD2		Any cancer type	[]		Pre-clinical
					SH2B3		Myelodisplasic proliferative syndrome	[]		Pre-clinical
					MET;ERBB2		Breast adenocarcinoma	Trastuzumab		Early trials
					SLC44A4		Prostate adenocarcinoma;Pancreas adenocarcinoma	[]		Pre-clinical
					SMARCA4		Ovary	[]		Case report
					SMARCB1		Malignant rhabdoid tumor	[]		Case report
					SMARCB1		Malignant rhabdoid tumor	[]	Clinical Trials	Early trials
					MET;ERBB2		Breast adenocarcinoma;Stomach	Trastuzumab		Early trials
					STK11		Lung adenocarcinoma	[]		Pre-clinical
					STK11		Any cancer type	[]		Pre-clinical
					STK11		Lung adenocarcinoma	[]		Pre-clinical
					STK11		Lung adenocarcinoma	Phenformin		Pre-clinical
					NF1		Cutaneous melanoma	Vemurafenib		Pre-clinical
					SUZ12		Any cancer type	[]		Pre-clinical
					SYK		Mantle cell lymphoma;Chronic lymphocytic leukemia	[]		Pre-clinical
					TMPRSS2		Prostate adenocarcinoma	[]		Pre-clinical
					TMPRSS2		Prostate adenocarcinoma	[]		Pre-clinical
					TOP2A		Breast adenocarcinoma	Anthracyclines		Late trials
					NF1;BRAF		Cutaneous melanoma	Vemurafenib		Case report
					NF1;BRAF		Cutaneous melanoma	Vemurafenib		Case report
					TP53		B cell lymphoma	AZD6738	Clinical Trials	Early trials
					TP53		Thymic	Pramlintide		Pre-clinical
					TPMT		Any cancer type	Cisplatin	Approved	FDA guidelines
					TPMT		Any cancer type	Mercaptopurine	Approved	FDA guidelines
					TPMT		Any cancer type	Thioguanine	Approved	FDA guidelines
					MET;BRAF		Colorectal adenocarcinoma	Vemurafenib;Panitumumab		Case report
					TSC1		Renal	Everolimus		Case report
					TSC2		Lymphangioleiomyomatosis	[]		Pre-clinical
					UGT1A1		Any cancer type	Irinotecan	Approved	FDA guidelines
					UGT1A1		Any cancer type	Nilotinib	Approved	FDA guidelines
					UGT1A1		Any cancer type	Pazopanib	Approved	FDA guidelines
					VEGFA		Hepatic carcinoma	Sorafenib		Early trials
